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ABSTRACT  
 Chronic HIV infection in the era of anti-retroviral therapy is associated with dramatically 
increased risk of developing severe cardio-pulmonary disease. Common to these diseases are 
increased oxidative burden and chronic inflammation despite low viremia and restoration of 
CD4+ T-cell levels. Soluble viral factors are heavily implicated in these disease processes, 
including the HIV Transactivator of Transcription (Tat). Tat is produced in high levels during 
infection and secreted from infected cells into circulation where it is internalized by bystander 
cells and is known to regulate inflammatory pathways and elicit a pro-oxidant environment. 
However, the mechanisms by which Tat induces a pro-oxidant cellular and tissue environment 
remain poorly described. It has previously been demonstrated that Tat down-regulates 
transcription of the critical mitochondrial antioxidant enzyme Superoxide Dismutase 2 (SOD2) 
by altering the binding ratio of the transcription factors Sp1 and Sp3 to the proximal (-210) 
region of the sod2 promoter. In this work, we have characterized the effect of Tat on Sp1/Sp3 
occupancy to the distal sod2 promoter and the resulting effect on SOD2 expression in primary 
human pulmonary arterial endothelial cells (HPAEC) as well as observed the effect of HIV 
infection on SOD2 levels in the lungs of HIV infected humanized mice. We found that Tat 
resulted in increased levels of SOD2, and that this effect was mediated at least in part by direct 
interaction of Tat with Sp3 resulting in reduced Sp3 occupancy to the distal sod2 promoter. 
Additionally, HIV infected mice demonstrated markedly increased levels of SOD2 in the lungs 
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as measured by IHC of lungs sections, although reduced total antioxidant capacity in the lungs of 
infected mice indicate that the lungs of these animals remain oxidatively stressed.  Furthermore, 
we have explored the effects of Tat on the redox regulatory nuclear factor (erythroid-derived 2)-
like 2 (Nrf2), which transactivates cytoprotective genes by binding to anti-oxidant response 
elements (ARE) in their promoter regions. Specifically, we have demonstrated that Tat represses 
Nrf2/ARE mediated transcription and results in increased levels of cellular and mitochondrial 
superoxide in a Tat expressing cell line. Tat also repressed basal transcriptional activity of 
Nr2/ARE driven antioxidant genes in HPAEC and desensitized cells to exogenous chemical 
stimulation of Nrf2.  
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Human Immunodeficiency Virus (HIV) 
HIV genome, structure, and life cycle 
 
 Human Immunodeficiency Virus (HIV) is an enveloped single stranded positive sense 
RNA (+ssRNA) virus within the family Retroviridae and is the causative pathological agent of 
acquired immune deficiency syndrome (AIDS). The HIV genome consists of two identical non-
covalently linked copies of positive sense RNA molecules. HIV, like all retroviruses, employs 
the unique strategy of reverse transcription in which the RNA genome is converted into a double 
stranded DNA (dsDNA) genome which is subsequently integrated into the host chromatin. 
Sequences known as long terminal repeats (LTRs) flank either side of the integrated genome 
(Fig. 1.1) and consist of several genetic elements which are critical to the viral life cycle 
including transcriptional trans-activation, genome packaging, primer binding, and genome 
dimerization. After integration, HIV employs an elaborate system of alternative splicing and 
ribosomal frameshifting in order to encode for 9 gene products within its 9.7 kb genome [1], [2]. 
Unspliced RNA transcript encodes the polyproteins group specific antigen (Gag) and polymerase 
(Pol), which are cleaved by the viral protease during virion maturation. Gag is encoded in the 
first open reading frame (ORF) while a -1 ribosomal frameshift reveals the Pol ORF [3]. The 
Gag precursor is processed into matrix (MA), capsid (CA), nucleocapsid (NC), and P6 structural 
proteins while the Pol precursor is cleaved into protease (PR), reverse transcriptase (RT), and 
integrase (IN). Partially spliced transcripts encodes the Envelope (Env), viral infectivity factor 
(Vif), viral protein R (VPR) and viral protein U (Vpu) genes while multiply spliced transcript 
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encode the Transactivator of transcription (Tat), negative factor (Nef) and regulator of 
expression of virion proteins (Rev) genes [4].  
 The mature HIV virion is a round particle of ~100 nM in diameter with a host cell 
derived lipid membrane serving as its envelope [5]. The HIV glycoprotein (Gp160) forms 
homotrimers in the viral envelope, with the Gp120 surface unit anchored by the Gp41 
transmembrane domain. Gp120 is critical to viral entry into host cells, as it mediates binding to 
CD4 receptors and CXCR4/CCR5 co-receptors expressed on the host cell surface, followed by 
fusion of the viral and host cell envelopes with subsequent delivery of the viral core [6]. The core 
is conical structure composed of  capsid protein and contains the viral genome as well as RT, PR, 
and INT [7]. Post entry, the RNA genome is reverse transcribed into a dsDNA genome in viral 
reverse transcription complexes (RTCs) followed by nuclear import and integration into the host 
cell genome [8].  
 Once integrated, HIV gene expression is defined by two phases: early and late. In the 
early phase, transcription of viral mRNAs is driven by constitutive and inducible cellular 
transcription factors, including the NF-kappa-B complex, Sp1, and Ap1 [9], [10]. Larger 
incompletely spliced products are not exported from the nucleus, while small multiply spliced 
products are transported out via cellular mechanisms and subsequently translated. These “early” 
genes include Tat, Rev, and Nef, and are expressed in a Rev independent manner [4]. Tat is the 
viral transactivator of transcription, and functions to dramatically enhance viral transcription by 
recruiting cellular transcriptional machinery to the viral transactivation response element (TAR) 
contained in the LTR, resulting in the formation of the super elongation complex and facilitating 
elongation of nascent viral transcript [11], [12]. Early expression of Nef, a multifunctional 
protein which enhances viral infectivity and facilitates immune evasion, serves to activate 
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infected T-cells and promote a more optimal cellular environment for viral replication [13]. Rev 
serves to export fully unspliced and/or partially spliced viral transcript from the nucleus where it 
is otherwise degraded by host nucleases. To accomplish this, Rev interacts with a highly 
structured RNA element in the Env gene known as the Rev Responsive Element (RRE) after 
which the Rev/RNA complexes are exported to the nucleus via the nuclear pore complex [14]. 
Once a sufficient amount of Rev has accumulated, the next phase is initiated, in which “late 
genes” including unspliced mRNA coding for the Gag/Pol polyproteins as well as spliced 
products encoding Vif, Vpr, and Vpu are exported from the nucleus and translated [15].  
 Viral assembly occurs when Gag traffics to the plasma membrane, followed by genomic 
viral RNA which is recruited to the NC domain of Gag through psi packaging element sequences 
in the 5’ UTR. Immature (un-cleaved) Gag is then packaged in a radial lattice, followed by 
packaging of Env which interacts with the MA domain of Gag [16], [17]. The immature virion 
then undergoes a membrane fission event, which is mediated by the P6 domain of Gag at the 
plasma membrane through its interaction with cellular ESCRT (endosomal sorting complexes 
required for transport) machinery [18], [19]. After the immature virion is released from the cell 
membrane, Gag is cleaved by the viral protease contained within the Gag/Pol polyprotein, thus 
triggering viral maturation. CA is cleaved and released from the Gag precursor in order to form 
the viral core around the genome, while NC binds and coats the viral genomic RNA. MA, which 
anchors Gag to the membrane in the maturing virion, forms the outer structural shell inside the 
envelope through which trimers of the Gp41 domain of ENV anchor trimers of Gp120 to the now 
mature and infectious virion [20].  
4 
 
HIV infection, AIDS, and anti-retroviral therapy 
HIV is the etiological agent of Acquired Immunodeficiency Syndrome (AIDS), which is 
defined by the CDC as a CD4+ T-cell count of <200 cells/µL or a CD4+ T-cell percentage of < 
14% in a patient infected with HIV. AIDS is characterized by a gradual loss of cellular immunity 
and host immunocompetence, driven in large part by depletion of CD4+ T-cells and consequent 
susceptibility to opportunistic pathogens and malignancies [21]. However, AIDS is a late stage 
manifestation of HIV infection and the result of a complex pathophysiological and virological 
process involving shifts in viral co-receptor usage and cellular tropism as well as defects in the 
humoral arm of adaptive immunity [22], [23]. CD4 is the primary receptor mediating HIV 
binding and is expressed on the surface of immune cells including T-cells, macrophages, 
monocytes, and dendritic cells. Equally important, however, are the chemokine co-receptors 
CCR5 and CXCR4 which are responsible for initiating host/viral membrane fusion after initial 
CD4 receptor binding [24], [25], [26], [27]. CCR5 and CXCR4 are 7 transmembrane domain G-
protein coupled receptors that function to transduce intracellular signals initiated by the binding 
of their respective chemokine ligands. CXCR4 is constitutively expressed on naive T-cells while 
CCR5 is expressed only on activated memory T-cells as well as monocytes and macrophages 
[28].  
HIV tropism is dictated by co-receptor usage, and viral isolates are classified thusly. 
Virus that utilizes CCR5 alone are classified as R5 viruses (or M-tropic) while those that utilize 
only CXCR4 are defined as X4 viruses (or T-tropic). Viral isolates capable of utilizing both co-
receptors are defined as R5X4 tropic and represent the earliest viral variant to utilize CXCR4 
during the course of infection.  A long-recognized phenomenon of HIV infection has been the 
observation that the virus undergoes an eventual shift in cellular tropism due to a switch in co-
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receptor utilization. While R5 tropic virus dominates early infection, an eventual switch to X4 
tropism is seen in a majority of HIV infected individuals [29]. Importantly, this shift correlates 
with accelerated CD4+ T-cell depletion and progression to AIDS [30]. Early infection with HIV 
constitutes the acute phase in which there is prolific viral propagation and an uncontrolled burst 
of viremia. The acute phase, typically peaking between 2 – 4 weeks post infection, is often 
accompanied by acute HIV-syndrome which manifests as flu like symptoms consisting of fever, 
headache, myalgia, and diarrhea [31]. The lymphocyte rich mucosal immune system is the 
primary target of HIV during early infection [32] in which R5 tropic virus dominates the viral 
population. Anatomical sites of high antigenic exposure and T-cell activation including gut 
associated lymphoid tissue (GALT) and the pulmonary immune system are particularly enticing 
targets for early infection and act as long-term reservoirs which contribute to viral persistence 
during the course of anti-retroviral therapy [33], [34]. Ensuing a host adaptive immune response 
there is a reduction in serum viremia and the viral load stabilizes at a level known as the viral 
set-point, initiating the chronic phase of HIV infection [35]. In the absence of antiretroviral 
therapy, the majority of patients will progress to AIDS, during which there is a prolific rebound 
in viremia as a result of the erosion of cellular and humoral immunity.  
Prior to the advent of anti-retroviral therapy (ART), infection with HIV and progression 
to AIDS was an almost invariably fatal condition due in large part to opportunistic pulmonary 
infections and AIDS associated malignancies. The nucleoside analog reverse transcriptase 
inhibitor (NRTI) Azidothymidine (AZT) is famously the first ART to be approved by the FDA, 
although the long-term survival benefits were minimal after 48 weeks of treatment [36]. NRTIs 
elicit antiviral effects through facilitating pre-mature chain termination during reverse 
transcription of the viral RNA genome into a complementary DNA genome. Nucleoside analogs 
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are converted into nucleotide analogs by host cellular kinases through the addition of a tri-
phosphate group to the deoxyribose moiety. These nucleotide analogs, however, lack a 3’- 
hydroxyl group, therefore inhibiting the formation of a phosphodiester bond between the 
following nucleotide to be incorporated and the nucleotide analog, resulting in premature chain 
termination and defunct viral DNA [37]. Following AZT, a number of other NRTIs were 
developed and implemented including the adenosine analog Didanosine and the thymidine 
analog Stavudine. However, a plethora of associated toxicities as well as evolutionary acquisition 
of NRTI resistance by HIV resulted in limited efficacy [38], [39]. The era of combinatorial anti-
retroviral therapy, otherwise known as highly active antiretroviral therapy (HAART) was 
ushered in with the advent of non-nucleoside analog reverse transcriptase inhibitors (NNRTIs) 
followed by viral protease inhibitors [40], [41]. The triple combination of NRTIs, NNRTIs, and 
protease inhibitors remains the gold standard for controlling HIV infection and preventing the 
progression to AIDS, and modern drug iterations with less severe toxicity profiles as well as 
once daily dosing regimens have improved treatment adherence and patient longevity. However, 
viral persistence in latent and active reservoirs and associated co-morbidities of chronic infection 
continue to present significant challenges to the long-term management of HIV infection.  
HIV persistence and chronic lung disease 
 Upon cessation of ART, HIV infected patients experience a prolific rebound in viremia, 
demonstrating the inability of modern therapy to completely eliminate the virus and rendering 
infection with HIV a chronic medical condition with unique challenges. The identity of the 
anatomical and cellular viral reservoirs which enable persistence during HAART continue to be 
the subject of debate. However, the lungs (amongst other anatomical sites including GALT and 
the CNS), continue to garner appreciation as a viral reservoir and site of viral replication during 
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the course of HAART. The lungs are a lymphocyte and monocyte rich system with a large 
mucosal surface by way of alveolar spaces and, much like the gut, is unique in its near constant 
exposure to antigenic stimulation from exogenous sources. The presence of HIV in the lungs was 
established in the pre-HAART era as evidenced by the presence of virus in various resident lung 
immune cells as well as in cell free bronchial alveolar lavage (BAL) fluid [42], [43]. Disparities 
in viral load and tropism in the lungs compared to peripheral circulating virus also implicate the 
lungs as unique sites of HIV infection and persistence. It has been demonstrated that BAL cells 
from HIV infected patients not receiving ART contain several fold more copies of proviral DNA 
than corresponding peripheral blood leukocytes [44] and that there is unique genotypic variation 
between pulmonary HIV isolates and peripheral blood HIV isolates, suggesting 
compartmentalized viral replication in the lungs [45], [46]. The preference for utilization of the 
CCR5 co-receptor in HIV lung isolates throughout the course of infection compared to 
heterogenous co-receptor usage in peripheral virus further suggests that there is distinct viral 
evolution in the lungs [47]. Importantly, HIV is also detectable in alveolar macrophages from 
patients on suppressive ART with un-detectable serum levels of virus [48]. It has additionally 
been demonstrated that HIV levels are approximately 13-fold higher in mucosal T-cells derived 
from HIV infected patients on long term HAART compared to peripheral blood monocytes 
(PBMCs) as measured by pro-viral DNA as well as cell-associated viral RNA [34]. It has been 
demonstrated that viral DNA can be utilized to accurately predict the frequency of HIV 
translation competent cells [49]. As such, these pulmonary immune cells have the potential not 
only to serve as a source to reseed the viral reservoir but as a source of extracellular viral factors 
which have the capacity to elicit deleterious effects on pulmonary bystander cells.  
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 While HAART significantly reduces the lung viral burden, chronic HIV infection is 
none-the-less associated with pulmonary immunological abnormalities as well as a number of 
non-AIDS associated chronic lung diseases [50], [51]. In the absence of anti-retroviral therapy, 
there are profound pulmonary immunological perturbations due to HIV infection which include 
increased concentrations and accumulation of pro-inflammatory mediators by way of constitutive 
generalized macrophage and T-lymphocyte activation [52], [53], a dramatic decrease in CD4+ to 
CD8+ T-cell ratio [54], CD4+ T-cell exhaustion [55], and a large increase in CD8+ T-cells 
which contributes to the development of lymphocytic alveolitis [56]. Implementation of HAART 
is associated with a dramatic decrease in cell free viral particles and viral RNA as well as 
decreased general immune cell activation in the lung. The CD4+/CD8+ T-cell ratio is also 
restored to near normal levels, although this is due primarily to a reduction in effector CD8+ T-
cells and not a prolific rebound in CD4+ T-cell numbers [57]. Alveolar macrophages, however, 
continue to demonstrate impaired phagocytic capacity after pulmonary immune reconstitution, 
which may contribute to the elevated levels of bacterial lung infections still seen in HIV patients 
receiving HAART [48]. Despite reduction in pulmonary viremia and reconstitution of the 
immune system to near normal states, pulmonary complications remain amongst the most 
common and severe sequalae of chronic HIV infection in the modern age of HAART. 
Significantly increased rates of multiple lung diseases independent of other known risk factors 
are seen within the HIV infected population including lung cancer, chronic obstructive 
pulmonary disease (COPD), pulmonary fibrosis, and pulmonary arterial hypertension (PAH) 
[51], [50]. Of particular interest is the dramatic increase in PAH seen amongst HIV patients. The 
relative rarity in the general population (1 – 15 in 1 million) compared to an approximately 1,000 
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fold increase in HIV patients (1 in 200) [58] warrants research into the viral and host 
mechanisms responsible for driving up the prevalence of this often fatal condition.  
 
HIV Associated Pulmonary Arterial Hypertension (HIV-PAH) 
Epidemiology of HIV-PAH 
Concomitant with the relative longevity afforded by HAART has been a dramatic 
increase in non-infectious cardio-pulmonary disease, including pulmonary arterial hypertension 
(PAH) [58], [59]. PAH, defined as a mean pulmonary arterial pressure (MPAP) of >20 Hg, a 
mean pulmonary artery wedge pressure (PAWP) of ≤15 mm Hg, and a pulmonary vascular 
resistance (PVR) of ≥3 wood units, is characterized by progressive obstruction of the small 
pulmonary arteries, resulting in increased pulmonary resistance and right ventricular load, 
ventricular hypertrophy, and frequently death [60]. The first case reports of plexogenic 
arteriopathy and pulmonary hypertension in HIV/AIDS patients were made in the late 1980s and 
early 1990s in which multiple HIV positive individuals presenting with unexplained dyspnea 
were, given the absence of evidence for secondary causes, diagnosed with primary (or 
idiopathic) pulmonary arterial hypertension [61], [62]. A retrospective study of 74 patients 
subsequently established the prevalence of PAH in HIV patients at 0.5%, approximately 2,000 
fold higher than in the general population [63]. In 1997, a Swiss cohort study revealed minimal 
benefit of retroactive administration of anti-retroviral therapy in a group of HIV-PAH patients to 
pulmonary arterial pressure [64], and In 2000  HIV infection was identified as a significant and 
independent risk factor for the development of PAH [65].  Although the incidence rate of PAH in 
the HIV infected population compared to the general population was striking, studies nonetheless 
suffered from the limitations of their relatively small sample sizes as well as gaps in knowledge 
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pertaining to the effects of global implementation of HAART. In 2008, the largest to date 
prospective study on HIV-PAH  prevalence, involving over 7,000 patients, revealed equivalent 
rates of HIV-PAH as those observed in the pre-HAART and early-HAART eras (0.5%), 
suggesting that HIV-PAH prevalence is largely independent of anti-retroviral therapy [66]. Other 
contemporary studies estimate the prevalence of HIV-PAH to be as high as 2.6 - 7.2% by 
transthoracic echocardiogram depending on diagnostic cutoff criteria [67]. However, the 
reliability of echocardiogram-based diagnosis of PAH is contested, and right heart 
catheterization remains the gold standard diagnostic tool. Additionally, it is important to note 
that studies have demonstrated that implementation of HAART in the early stages of HIV-PAH 
improves  pulmonary artery pressure [68], though antiviral treatment at more advanced stages 
demonstrate no benefit. While the epidemiological incidence has been well established, the 
mechanisms driving the prevalence of PAH in the HIV infected population remain relatively 
opaque, and understanding how interactions between HIV and the host at the cellular/molecular 
interface drives the progression of PAH represents a unique opportunity to shed light on a 
relatively enigmatic disease process.  
Pathophysiology of HIV-PAH 
 It is increasingly apparent that PAH is a disease with complex and heterogeneous cellular 
and molecular pathologies, and options for therapeutic intervention are limited, resulting in poor 
clinical outcomes for affected patients. The overlapping features of PAH cellular pathologies and 
effects of viral factors on related cell types provide clues as to the potential mechanisms driving 
HIV-PAH etiology and progression. HIV-PAH, like idiopathic PAH (iPAH), involves 
progressive remodeling of the small pulmonary arteries, characterized by neo-intimal endothelial 
hyperplasia, medial smooth muscle cell hypertrophy and arterial muscularization [69] (Fig.1.2). 
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These plexogenic lesions were previously thought to be late stage symptoms of PAH, resulting 
from prolonged vasoconstriction and vascular inflammation. However, more modern hypotheses 
suggest a chronological model of disease progression in which the formation of veno-occlusive 
structures is an initiating factor of PAH, progressively resulting in severe hemodynamic 
perturbations and increased arterial pressure, though this is still the subject of some debate [70], 
[71], [72].  Though there are varying and sometimes disparate hypotheses as to the causes and 
origins of these abnormal pathological vascular structures [73],  lessons can be learned from the 
identification of genetic causes in hereditary PAH (hPAH) as well as modern observations of 
many cancer like properties often observed in the cells that constitute concentric and plexiform 
arterial lesions. Studies have demonstrated a role for monoclonal expansion of endothelial cells 
(ECs) in the development of iPAH [74], [75], as well as quasi-neoplastic cellular properties 
including pro-proliferative and anti-apoptosis phenotypes [76], [77].  Accordingly, PAH ECs 
also demonstrate genomic instability and a predisposition to accumulate somatic mutations [78]. 
Genetic bone morphogenic protein receptor 2 (BMPR2) deficiency is associated with familial 
PAH[79], [80] and vascular oxidative injury is a prevailing consequence of loss of BMPR2 
function [81], [82], potentially contributing to genomic instability and pro-inflammatory 
phenotypes of PAH vascular ECs.  Furthermore, commonalities across various types of PAH 
(hPAH, iPAH, associated PAH) offer unique insights into potential common etiologies.     
The role of oxidative stress in pathogenesis  
 When appropriately regulated under physiological conditions, ROS play important roles 
in homeostatic hemodynamic regulation and vascular tone. Nitric oxide (NO) is produced by 
endothelial Nitric Oxide Synthase (eNOS) and is critical to the maintenance of vascular tone 
[83], cell growth [84], and vascular injury response [85], and the hydroxyl radical (•OH), a 
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derivative of the superoxide anion (O-2) stimulates cGMP signaling, an important mediator of 
vascular SMC plasticity [86], [87].  However, the volatile and reactive nature of ROS has 
necessitated the evolution of numerous mechanisms to regulate the production and dismutation 
of free radicals which is essential to the viability of all aerobic life. Oxidative stress occurs when 
the production of ROS outpaces the ability of a biological system to detoxify reactive 
intermediates and repair resulting macromolecular damage. This can occur as a consequence of 
excessive ROS production, reduced detoxification capacity (downregulation and/or inhibition of 
superoxide dismutase enzymes) or a combination of both. The result is oxidative modifications 
and damage to cellular macromolecules including proteins, lipids, and DNA/RNA, resulting 
often in significant tissue damage, inflammation, mitochondrial dysfunction, alterations to 
normal metabolic processes, and significant DNA damage.   
 Altered redox states and markers of chronic oxidative stress in the lungs of animal 
models of PAH as well as the lungs of PAH patients has warranted the study of aberrant redox 
biology as a contributing factor to the potential initiation and development of PAH 
pathophysiology. The monocrotaline (MCT) induced rat model of pulmonary hypertension is 
amongst the most common animal models for the study of PAH and recapitulates several key 
characteristics of human PAH including vascular remodeling, increased inflammatory cytokine 
production, and pro-proliferative EC and SMC phenotypes [88]. The rat MCT model of PAH is 
also characterized by an increased pulmonary oxidative burden, and treatment with antioxidant 
compounds prevents the development of PAH in these animals [89]. Other common animal 
models of PAH, including chronic hypoxia, Caveolin-1 knock-out, and neonatal animal models 
of PAH demonstrate increased pro-oxidant enzyme activity as well as increased ROS levels and 
biomarkers of pulmonary oxidative injury [90], [91], [92]. There is evidence to support a role for 
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oxidative stress in the role of PAH pathogenesis in humans as well such as increased endothelial 
xanthine oxidase activity [93] and pro-survival antioxidant response gene products such as 
thioredoxin, metallothionein, and glutathione [94]. Furthermore, biochemical markers of severe 
oxidative damage are present within the vascular lesions of patients with idiopathic as well as 
secondary pulmonary arterial hypertension.  Immunohistochemical analysis reveals dramatically 
increased levels of 8-hydroxy guanosine (8-HG), an oxidative derivative of guanosine, as well as 
oxidative cellular damage as measured by nitrotyrosine staining. Interestingly, IHC stains from 
emphysema patients demonstrate relatively little oxidative damage, suggesting a specific role for 
oxidative stress in PAH [95]. While these data are correlative and do not explore the temporal 
relevance to PAH pathogenesis, other studies have revealed a role for oxidative stress in the 
initiation of PAH in humans. It has been demonstrated that increased ROS production in PAH 
patients correlates with DNA damage and chromosomal instability as well as increased mutagen 
sensitivity, and these phenotypes were reversible in explanted cells with the administration of 
antioxidant compounds. Furthermore, baseline DNA damage as well as mutagen sensitivity was 
similar amongst unaffected relatives of PAH patients (without BMPR2 mutations) suggesting a 
genetic predisposition for the development of PAH for which excess oxidative stress could be a 
catalyst [96].  
 A long-recognized consequence of HIV infection has been elevated levels of systemic as 
well as localized oxidative stress and inflammation. Total antioxidant capacity (TAC) is a 
generalized biomarker used to assess the global anti-oxidant state of a biological systems, and 
common modern methods include colorimetric and spectrophotometric analysis of the ability of 
a sample to reduce positively charged copper and/or iron chromogens [97], [98], [99]. Numerous 
studies have demonstrated markedly reduced serum TAC in HIV infected patients, indicating 
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systemic perturbations to patient redox regulatory mechanisms. Furthermore, serum TAC in 
these patients correlates with oxidative markers of macromolecule damage including lipid 
peroxidation by measurement of  malondialdehyde (MDA) and lipid hydroperoxides [100], 
[101]. HIV patients also demonstrate systemic oxidative DNA/RNA damage as evidenced by the 
excessive accumulation of oxidized base residues [102]. Glutathione (GSH), is the predominant 
antioxidant found in the lungs and enhances antioxidant capacity by reducing free radicals and 
becoming oxidized into glutathione disulfide (GSSG), and research has demonstrated a dramatic 
reduction (up to  60%) in pulmonary GSH in HIV infected patients compared to healthy controls 
[103], likely as a result of excessive oxidation of GSH resulting in its sequestration in its 
oxidized GSSG form. Animal models recapitulate the enhanced oxidative stress seen in HIV 
infected humans. Rhesus Macaques infected with a chimeric SIV/HIV (SHIV89.6P simian virus 
expressing human Tat, Rev, Vpu, and Env) virus exhibit elevated levels of lipid peroxidation as 
well as reduced serum TAC [104], and HIV infected humanized mice demonstrate reduced lung 
TAC [105]. HIV transgenic models additionally display the pro-oxidant properties of HIV/SHIV 
infected animal models and HIV infected humans. The NL4-3Δ gag/pol Tg26 (Tg26) mouse is a 
generalized model of HIV infection that has been widely used to study HIV and AIDS associated 
co-morbidities [106]. Tg26 mice are hemizygous for the NL4-3 HIV genome with a large 
internal deletion in the Gag and Pol coding regions and allow for research in the absence of 
infectious/replication competent virus. Tg26 mince exhibit a number of redox pathologies 
including elevated levels of ROS which correlates with the presence of oxidative DNA lesions 
[107]. Furthermore, Tg26 mice demonstrate increased pulmonary edema and superoxide levels 
in lung tissue sections as well as increased nitrate/nitrite levels in bronchial alveolar lavage fluid 
and increased levels of protein nitrosylation in the lungs [108]. HIV transgenic rats have also 
15 
 
been utilized to research chronic HIV co-morbidities. Rats are additionally known to 
demonstrate pulmonary vascular remodeling, a trait generally lacking in mouse models, making 
them particularly useful for the study of PAH pathogenesis. In one, study, HIV transgenic rats 
exhibited PAH with concomitant vascular remodeling of small pulmonary arteries and right 
ventricular hypertrophy [109]. The fact that replication competent virus is not necessary to 
induce severe pulmonary oxidative stress as well as elicit a PAH phenotype has led the field to 
shift focus towards the effects of soluble viral factors on bystander cells involved in PAH 
pathogenesis. In particular, Gp120, Nef, and Tat have garnered the most attention.   
Soluble HIV Factors and HIV-PAH 
Gp120 and Nef 
 Soluble HIV factors are extracellular viral proteins found in circulation as well as in 
various tissues of HIV infected patients, and may be released from infected cells through 
numerous mechanisms including secretion in extracellular vesicles, unconventional secretion 
through interactions with specific phospholipids at the inner leaflet of the cell membrane, or 
release through cell death. Gp120, which has been detected in patient serum in the ng/mL range 
[110], is known to contribute to endothelial dysfunction by potentiating endothelial apoptosis as 
well as inducing secretion of endothelin-1, a potent vasoconstriction factor and therapeutic target 
in pulmonary hypertension [111], [112]. In addition to contributing to endothelial dysfunction, 
Gp120 is additionally known to have mitogenic effects on vascular SMCs through stimulation of 
the neuropeptide Y receptor, potentially contributing to arterial muscularization seen in HIV-
PAH [113].  
Nef is perhaps the most extensively researched soluble HIV factor in terms of HIV-PAH 
pathogenesis. Rhesus macaques infected with a chimeric SIV virus expressing the HIV Nef 
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protein (SHIV-nef) develop lung vascular lesions that are histologically similar to those seen in 
HIV-PAH patients, while animals infected with parental SIV strains presented with no such 
pathologies. Common pathological features included intraluminal obstruction due to endothelial 
cell proliferation as well as medial thickening as a result of SMC hypertrophy. Furthermore, 
immunofluorescent staining of SHIV-nef infected animal lung sections reveals co-localization of 
Nef with arterial endothelial cells, but not in SIV infected macaques, suggesting properties 
unique to the HIV Nef which contribute to its putative pathological features in the pulmonary 
vasculature. Additionally, Nef has been seen to co-localize with endothelial cells in the vascular 
lesions of patients with HIV-PAH [114]. It was later revealed that certain HIV Nef 
polymorphisms are associated with the development of HIV-PAH, although the functional 
relevance of these mutations to PAH pathogenesis have yet to be determined [115]. It has, 
however, been demonstrated that Nef is transferred to endothelial cells from infected T-cells, and 
that this event potentiates endothelial dysfunction [116]. Furthermore, pro-survival phenotypes 
elicited by Nef through modulation of the AKT/PI3K signaling axis may contribute to the anti-
apoptotic and pro-proliferative endothelial phenotypes common to HIV-PAH [117].  
The HIV Transactivator of transcription (Tat) 
 The HIV Transactivator of Transcription (Tat) is a small pleiomorphic protein that 
represents a research target of particular interest due to a number of unique biological and 
molecular properties. Virologically, Tat is essential to HIV replication due to its roles in 
facilitating and regulation viral transcription. Tat functions to transactivate transcription of 
integrated proviral DNA through interactions with motifs in the LTR known as trans activation 
response elements (TAR) where it recruits the RNA polymerase elongation factor P-TEFb, 
consisting of CDK9 and cyclin T1 subunits [118], [119]. Tat is additionally involved in 
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modulation of host cellular factors to facilitate viral replication and persistence. For instance, Tat 
is known to inhibit the acetyl-transferase Tat-interaction protein 60 kDa (Tip60) in order to 
impair apoptosis in T-lymphocytes, a strategy that allows infected cells to resist HIV related 
genotoxic stress  induced cell death [120]. A long-recognized property of Tat, however, is that it 
is actively secreted from infected cells into the extracellular milieu, where it is internalized by 
uninfected bystander cells by means of a cell penetrating peptide in its basic core domain, which 
also contains a nuclear localization signal [121], [122], [123]. Once internalized, Tat traffics to 
the nucleus, where it is known to modulate a number of transcriptional and post transcriptional 
cellular processes [124]. Interestingly, Tat is detectable in the ng/mL range in sera of HIV-
infected patients, despite treatment with HAART, and the amount of Tat detected does not 
appear to correlate with plasma viral load or CD4+ T cell count [125], [126]. While the 
mechanism of Tat internalization and trafficking to the nucleus have been well described, the 
means by which Tat is released into the extracellular environment has been a subject of some 
controversy. However, recent research has revealed an unconventional mechanism of Tat 
secretion via accumulation at the plasma membrane through a necessary interaction with 
phosphatidylinositol-4,5-bisphosphate. Furthermore, it is estimated that ~2/3 of Tat produced 
over the lifespan of a primary T-cell is exported, suggesting an important role for extracellular 
Tat in the propagation of successful HIV infection [127]. Extracellular Tat has various 
pleiotropic effects on the bystander cells with which it interacts, with modulation of redox 
regulatory and inflammatory pathways being amongst the most prominent [124], [128], [129]. 
As Tat is internalized rapidly by proximal bystander cells, the majority of extracellular Tat in 
patients receiving HAART is likely sequestered primarily in tissues which comprise viral 
reservoirs. Indeed, a myriad of oxidative and inflammatory diseases are associated with HIV 
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reservoirs including the gut, CNS, and lungs [130], [131]. As such, the mechanisms by which Tat 
elicits a pro-oxidant cellular state represent an enticing target of therapeutic interest.  
HIV Tat and redox sensitive transcription factors 
 The observation that Tat represses Superoxide Dismutase 2 (SOD2), a critical 
mitochondrial antioxidant enzyme, provided early clues as to the mechanisms by which Tat may 
dysregulate cellular redox homeostasis and contribute to HIV co-morbid disease pathogenesis 
[132]. It was later revealed that Tat repression of SOD2 was mediated through specificity 
transcription factors (Sp) 1 and 3. In particular, Tat induced an increase in Sp3 occupancy of the 
proximal sod2 promoter region, resulting in base line repression of SOD2 [133], [134]. However, 
the effects of Tat on the much larger distal promoter region in physiologically relevant non-
transformed cells remained to be explored. This thesis work has demonstrated that, contrary to 
previous observations in transformed epithelial cell types, SOD2 expression was enhanced by 
Tat, and that this effect seemed to be mediated at least in part by a Tat/Sp3 interaction, resulting 
in decreased occupancy of Sp3 to the more distal -584 region of the sod2 promoter. Furthermore, 
this effect was recapitulated in the lungs of HIV infected humanized mice, and these results are 
in line with observations in the lungs of a Tat transgenic mouse line. However, TAC assays 
revealed that, although SOD2 expression was enhanced, lungs of the HIV infected humanized 
mice remained significantly oxidatively stressed, suggesting alternative roles of redox 
dysregulation in vivo.  
 While SOD2 is a critical redox regulatory enzyme, it is a singular component of a larger 
multinetwork system of redox regulatory mechanisms. The transcription factor  nuclear factor 
erythroid-derived 2-like 2 (Nrf2) regulates the transcription of cytoprotective antioxidant genes 
in response to oxidative injury and/or inflammation [135]. Under normal physiological 
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conditions, Nrf2 remains sequestered in the cytosol bound to its repressor Keap1, a ubiquitin 
ligase adaptor protein which facilitates the constant degradation of Nrf2. However, activation by 
free radical/electrophile sensing results in the release of Nrf2 from Keap1 and consequent 
stabilization and shuttling of Nrf2 into the nucleus [136]. Nuclear Nrf2, along with small maf 
protein co-activators, bind to consensus sequences in the promoter region of a myriad of 
antioxidant genes known as the anti-oxidant response element (ARE) resulting in transactivation 
of gene expression [137]. Given its particular importance in the maintenance of redox 
homeostasis in the lungs, previous observations of modulation of Nrf2 by HIV in macrophages 
[138], and Tats propensity to interact with various cellular transcriptional factors, the Nrf2/ARE 
network represented an enticing research target. We have demonstrated that Tat represses 
Nrf2/ARE transcriptional activity and represses the expression of numerous cytoprotective genes 
as well as increased cytoplasmic and mitochondrial superoxide levels as measured by electron 
paramagnetic resonance spectroscopy. Furthermore, Tat de-sensitizes HPAEC to exogenous 
chemical activation of Nrf2/ARE driven transcription, suggesting a strong predilection of Tat to 
repress Nrf2/ARE antioxidant genes. Taken together, these results may provide clues as to the 
mechanisms of HIV mediated oxidative lung injury despite elevated levels of Sod2 in the lungs 












Fig. 1.1 Organization of the HIV-1 genome. The HIV genome is flanked by two long terminal 
repeat sequences which participate in the orchestration of primer binding, viral transcriptional 
activation, genome packaging, and genome dimerization. The first ORF encodes the group 
specific antigen (Gag) poly protein which is subsequently cleaved by viral protease into matrix 
(MA), capsid (CA), and nucleocapsid (NC) proteins. The N-terminal P6 polypeptide of Gag 
participates in the initiation of viral assembly and budding by recruiting host ESCRT molecular 
machinery. A -1 ribosomal frameshift reveals the POL open reading frame, another HIV 
polyprotein which is proteolytically cleaved into viral protease (PR), reverse transcriptase (RT) 
and integrase (IN). Partially spliced viral RNAs encode the ENV gene which contains the Gp120 
and Gp41 units of the HIV Gp160 glycoprotein. Completely spliced viral gene products encode 
for the Transactivator of transcription (Tat) and the regulator of expression of virion proteins 
(Rev) as well as the so called accessory proteins, which include the virulence factors negative 












Figure 1.2: Histopathology of iPAH and HIV-PAH plexogenic vascular lesions. A. Normal 
pulmonary artery. B. Plexiform lesion from iPAH patient demonstrating endothelial hyperplasia 
and neo-intimal obliteration. C. Plexiform lesion from HIV-PAH demonstrating disordered 


















Table 1.1 Markers of oxidative damage in HIV patients. 
 
 
Table 1.2 Animal models of infection are oxidatively stressed 
 
 











Redox Pathology As measured by Ref.
Serum Ferric reducing antioxidant power Suresh, D. R., et. al.J. Biomed. Sci. 16, 61 (2009).
Diacron's reactive oxygen metabolites test
Derivatives of reactive oxygen metabolites test
Oxidative DNA/RNA Lesions 8-oxoguanine, 5-hydroxycytosine, and 8-hydroxyguanine Aukrust, P. et al. Blood 105, 4730–4735 (2005).
Protein Damage Protein carbonyl content Piedimonte, G. et al. J. Infect. Dis. 176, 655–664 (1997).
Serum malondialdehyde Suresh, D. R., et. al.J. Biomed. Sci. 16, 61 (2009).
Lipid Peroxidation Favier, A. et al. Chem. Biol. Interact. 91, 165–180 (1994).
Coaccioli, S. et al. Clin. Ter. 161, 55–8 (2010).
Reduced total antioxidant capacity
 Lipid Damage
Model Redox Pathology Ref.
Oxidative DNA/RNA Lesions Salhan, D. et al. Am. J. Physiol. - Ren. Physiol. 303, F503 (2012).
Increased nitrate/nitrite in lung tissue/BALF/Serum
Increased nitrotyrosine in lung sections
Elevated plasma 8-isoprostane and GSSG Mak, I. T. et al.  Int. J. Mol. Sci. 19, (2018).
Increased nitrotyrosine in lung sections
Dysregulated expression of antioxidant genes
Jacob, B. A. et al. Am. J. Physiol. Cell. Mol. Physiol. 291, L811–L819 (2006).  
Mak, I. T. et al.  Int. J. Mol. Sci. 19, (2018).
NL4-3Δ gag/pol Tg26 




HIV TAT MODULATION OF SP1/SP3 ACTIVITY AND SOD2 EXPRESSION IN 
HPAEC AND A MOUSE MODEL OF HIV IFNECTION 
Introduction 
Cellular and systemic oxidative stress is an established consequence of HIV infection, 
and while modern anti-retroviral therapy has been widely successful in mitigating the AIDS 
epidemic, HIV patients remain chronically infected and exhibit biomarkers of increased 
oxidative stress. Accordingly, HIV infected patients are at a dramatically increased risk of 
systemic inflammatory diseases, and the chronic oxidative stress elicited by HIV infection is 
thought to be a driving factor of these pathologies [51], [139]. While a number of viral factors 
have been implicated in these pro-oxidant processes, the molecular mechanisms by which they 
evoke such oxidative biological environments remain relatively thinly researched. However, an 
early clue in the field of HIV related oxidative stress came with the observation that the HIV 
Transactivator of Transcription (Tat) downregulated expression of the Manganese-containing 
Superoxide Dismutase, SOD2 [132]. Tat is an early HIV gene that is responsible for 
transactivation of viral gene transcription from the long terminal repeat of integrated proviral 
DNA and is therefore integral to the life cycle of the virus [11], [12]. Interestingly, Tat is 
secreted from infected cells into the extracellular environment where it is internalized by 
uninfected bystander cells and is known to interfere with cellular function by modulating a 
number of transcriptional pathways [120], [140]. In this capacity, Tat acts as a bridge linking 
HIV infected cells to the larger extracellular environment. SOD2 is a mitochondrial antioxidant 
enzyme that is integral to the maintenance of cellular redox homeostasis by way of catalyzing the 
conversion of the highly potent ROS, superoxide (O2
. ), to hydrogen peroxide and diatomic 
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oxygen. Mutations in the sod2 gene are associated with a wide array of diseases including cancer 
respiratory, cardiovascular and neurodegenerative diseases [131], [141], [142]. Furthermore, it 
has been demonstrated that mutant mice lacking SOD2 die as neonates due to cardiomyopathy 
and oxidative mitochondrial injury, and that overexpression of the cytosolic CuZnSOD in these 
mice could not compensate for the loss of SOD2 [143]. As such, the observation that Tat 
repressed SOD2 expression warranted further research into the mechanisms governing this 
response. Transcriptional regulation of SOD2 is cell-specific and sensitive to a number of 
exogenous factors including oxidative stress and inflammation [144]. The human sod2 promoter 
sequences immediately flanking the transcription initiation site contain a TATA-less region of 
high GC content with multiple Sp and AP binding sites [145]. Xu et al. demonstrated this region 
constitutes the basal sod2 promoter, and that Sp factors are important regulators of sod2 
expression. They determined the relative basal transcriptional activity of constructs extending 
upstream of −210 nucleotides and found that a construct extending out to −555 nucleotides 
exhibited maximal transcription, 2-fold higher than the −210 construct, and that there was no 
more increase in transcriptional activity with any fragment extending beyond −555 nucleotides. 
Subsequently, we demonstrated that Tat regulated basal sod2 promoter activity by altering the 
binding activity of transcription factors Sp1 and Sp3 to the proximal promoter region (−73 to 
−123 nucleotides) [133]. Furthermore, in a Tat transgenic mouse line, we observed increase 
biomarkers of oxidative stress as well as lung cellular infiltrate, though overall SOD2 was 
increased, suggesting a compensatory physiological response to Tat mediated injury [128]. 
Previous work attempting to elucidate the mechanisms by which Tat modulates SOD2 has relied 
on transformed cell lines as well as Sp1/Sp3 deficient drosophila S2 cells and focuses only on the 
proximal promoter region, −210 nucleotides from the transcriptional start site. Here, in an effort 
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to further characterize Tat mediated basal regulation of sod2, we performed an in-silico analysis 
of the sequences further upstream of the human sod2 proximal promoter, between nucleotides 
−3406 to −210 from the transcriptional start. We found several clusters of Sp binding sites of 
varying strengths (Fig. 2.1) and hypothesized that, as with the Sp clusters contained in the −210 
region, these distal sites are also regulated by Tat. In a physiologically relevant cell system, 
primary human pulmonary arterial endothelial cells (HPAEC), we determined the effects of Tat 
on transcription from these distal Sp-binding clusters. In this report, we demonstrate that a 
cluster of Sp binding sites located near the −584 region is required for maximal transcription and 
is exquisitely sensitive to Tat. Thus, this distal Tat-sensitive site (DTSS) is an important cis-
acting factor in Tat-mediated sod2 regulation in HPAEC. We also show that in HPAEC, Tat 
alters the binding pattern of Sp1 and Sp3 to the chromosomal DTSS, as well as expression of 
Sp1 and Sp3 and that Tat directly binds to Sp3 but not Sp1. Furthermore, we observed altered 
Sp1 and Sp3 levels in the lungs of HIV-1 infected humanized mice. 
Materials and Methods 
Cell culture 
Wild-type HeLa (ATCC) and HeLa-TatIII cells (NIH AIDS Reagent Program) were grown in 
OPTI-MEM (Invitrogen Life technologies) supplemented with 3.75% Heat-inactivated fetal 
bovine serum (Atlanta Biologicals) and 1X Antibiotic/Antimycotic (Invitrogen Life 
technologies). HeLa-TatIII media also contained 500 μg/mL G418 (Sigma). Primary Human 
Pulmonary Artery Endothelial cells (HPAEC, from Lonza) were maintained in EGM2-MV 
media, (Lonza). All cells were grown in a 37 °C incubator containing 6.5% CO2, washed with 
1X phosphate buffered saline (PBS, filter-sterilized) and fed fresh medium every 2–3 days. 
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In silico identification of putative sod2 upstream regulator regions 
To identify possible novel Sp-regulatory regions upstream of the sod2 start site (TSS), the 
promoter region 3400 nucleotides upstream of the sod2 transcriptional start site, hereafter 
referred to as −3400sod2, was scanned using the openware software packages MatInspector and 
PhysBinder. Fig. 2.1 depicts the putative Sp-binding clusters identified. 
sod2 promoter-luciferase constructs 
Dr. Daret St. Clair generously provided a series of sod2 promoter reporter constructs in 
the pGL3B backbone with luciferase expression under the control of increasingly longer sod2 
upstream sequences (Fig. 2.1B) [146]. The −210, −1240, −1605, −2987 and −3400 constructs 
from Dr. St. Clair were used in this study. A sixth construct, containing -584 sod2 promoter 
region (pGL3B-584sod2) was generated in house. To accomplish this, a 608 bp fragment 
between −584 and + 24 nucleotides of the sod2 TSS was amplified by PCR with engineered 
KpnI and BglII restriction sites in the 5′ and 3′ primers respectively. Due to the high GC content 
of this region, a high-fidelity DNA polymerase (AccuPrime, Invitrogen) as well as 7-deaza-GTP 
was employed. The resulting product as well as pGL3B parent vector were digested with KpnI-
HF and BglII-HF (New England BioLabs). The resulting digests were then cleaned (PCR Clean 
kit, Qiagen) and ligated into the digested pGL3B  parent vector utilizing standard ligase reaction 
conditions (Invitrogen). Plasmid was then transformed into chemically competent E. coli DH5α 
following the manufacturer's protocol (Stratagene) and selected with LB-agar plates containing 
100 μg/ml of ampicillin. Colonies were screen using PCR and restriction analysis, and positive 
clones were confirmed by sequencing.   
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Transfections and dual luciferase 
In order measure sod2 transcriptional activation, promoter-reporter plasmids expressing 
luciferase under the control of increasingly longer sod2 upstream sequences were utilized (Fig. 
2.1) in HPAEC, HeLa WT and HeLa-TatIII cells. Cells were transiently transfected using 
Superfect transfection reagent according to the manufacturer's protocol (Qiagen). HeLa WT and 
HeLa-TatIII cells were transfected with 1 μg of total DNA (0.5 μg of sod2 promoter-reporter 
plasmid and 0.5 μg of a CMV driven Renilla luciferase plasmid). HPAEC were additionally co-
transfected with 0.5 μg of the Tat-expressing plasmid pCP2-Tat101. Twenty-four hours post 
transfection, luciferase was measured using the Dual Luciferase Reporter Assay System 
(Promega) according to the manufacturer's instructions in a dual injector MicroPlate 
Luminometer (Promega). All luminescence data was normalized to Renilla luciferase signal. 
Chromatin immunoprecipitation 
Using Superfect transfection reagent (Qiagen), HPAEC (approximately 2 × 106 cells per 
dish, six dishes per transfection) were either mock transfected or transfected with 5 μg of pCP2-
Tat101 plasmid. Twenty-four hours post transfection, cells were cross-linked with 1% 
formaldehyde and quenched with 1X glycine followed by two consecutive washes with ice-cold 
1X PBS. Cells were collected via scraping in 1X PBS supplemented with protease and 
phosphatase inhibitors and centrifuged at 3000×g for 5 min. Following the manufacturer's 
instructions, the Pierce Agarose ChIP Kit (Thermo Scientific) was used to precipitate and clean-
up DNA bound by either control IgG (3 μg rabbit or mouse IgG provided in the kit), anti-Sp1 
rabbit polyclonal (3 μg, ChIP-grade, Abcam) or Sp3 mouse monoclonal (3 μg, ChIP-grade, Santa 




Immunoblots, immunoprecipitation and DNA-binding ELISAs 
 Immunoprecipitations were carried out from 1-4 mg of total cellular protein with 3 μg of 
antibody per mg of protein following standard protocols [147]. For immunoblots, total protein 
was extracted from cells using Mammalian Protein Extraction Reagent (Thermo Fisher) 
supplemented with 1 mM DTT and 1X Protease/Phosphatase inhibitor cocktail (HALT, Thermo 
Fisher). For immunoblot analysis, proteins were resolved by Sodium dodecyl sulfate (SDS) poly-
acrylamide gel electrophoresis, transferred to Polyvinylidene fluoride (PVDF, BioRad) and 
detected with antibodies from commercial sources. Mouse monoclonal antibody to Tat was from 
the AIDS Reference Reagent Program [148]. Immunoblots were imaged by chemiluminescence 
using Supersignal West Femto Maximum Sensitivity substrate (Thermo Fisher) on a Kodak 
Image Station 440 CF and Kodak 1D imaging software. Background was subtracted from the 
densitometric net intensity values of the target protein and the loading control (β-actin), which 
was used to normalize the signal of the target protein. DNA-binding ELISAs for active Sp1 and 
Sp3 were carried out on nuclear extracts prepared as previously described [124] using Sp1 and 
Sp3-specific TransAM kits (Active Motif) according to manufacturer's protocol. 
Generation and HIV infection of humanized NSG-BLT mice 
Humanized, NSG-BLT, mice were generated at the Humanized Mouse Core of the 
University of Massachusetts Medical School, as previously described [149]. NOD-scid IL2rg-
null mice at 6–8 weeks of age were implanted with human fetal thymic and liver tissue 
(Advanced Bioscience Resources, In., Alameda, CA) and transplanted with autologous human 
hematopoietic stem cells (hCD34+) derived from the fetal liver. In BLT mice, T-cells are 
autologously educated by the human thymic tissue, and the mice develop a robust human 
immune system comprised of multiple human cell lineages with sustained high levels of human 
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T-lymphocytes for several months. At 12 weeks post tissue engraftment, BLT mice were 
monitored by flow cytometry for human immune system development. Levels of human CD45 + 
cells (clone HI30, BD Bioscience), CD3+ T cells (clone UCHT1, BioLegend) and CD20 + B 
cells (clone 2H7, BioLegend) were measured. Engrafted BLT mice were shipped to the 
University of Colorado where they were quarantined for 1 week and then housed in a pathogen-
free BSL3-equipped animal laboratory. 
Detection of HIV DNA and cell-free RNA in NSG-BLT mice 
Nested PCR was employed in order to validate HIV infection in NSG-BLT mice. Two 
primer pairs (outer and inner reactions) specific to Env sequences were designed and used in 
PCR on total DNA extracted from homogenized liver tissue. HIV infection in the lung was also 
confirmed 10 weeks post infection utilizing the same nested PCR system from whole lung tissue 
homogenate. Plasmid pBR-NL43-IRES-eGFP-nef+ (AIDS Reference Reagent Program), 3.5 fg, 
served as the positive control while no template reactions served as negative controls. 
Bronchoalveolar lavage (BAL) was performed as previously described [128] and cleared of cells 
by centrifugation at 600×g for 15 min at 4 °C. RNA was extracted from the cell-free BAL fluid 
(supernatant) using QIAamp UltraSens Viral Kit (Qiagen) and cell free viral RNA was detected 
by RT-qPCR utilizing the iTaq Universal SYBR green Onestep RT-qPCR SYBR supermix 
(BioRad), demonstrating a productive infection in the lungs. To generate a template for a 
standard curve for the HIV RT-qPCR, a 541 bp fragment of the Env gene was generated using 
the outer primers of the nested PCR and cloned it into pCR2.1 plasmid via T-A ligation with the 
TOPO T-A cloning system (Invitrogen Life Technologies) resulting in plasmid pCR2.1-Env541. 
All clones were confirmed via sequencing.  
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Detection of Sp1, Sp3 and SOD2 proteins in lungs of NSG-BLT mice 
For detection of Sp1, Sp3 and SOD2 in the lungs of HIV infected NSG-BLT mice, total 
protein was extracted from lung tissue homogenates using Tissue Protein Extraction Reagent 
(Thermo Fisher) supplemented with 1 mM DTT and 1X Protease/Phosphatase inhibitor cocktail 
(HALT, Thermo Fisher). For immunoblot analysis, samples were resolved by Sodium dodecyl 
sulfate (SDS) poly-acrylamide gel electrophoresis, transferred to Polyvinylidene fluoride (PVDF, 
BioRad) and detected with antibodies from commercial sources. Chemiluminescent signal was 
detected with Supersignal West Femto Maximum Sensitivity substrate (Thermo Fisher) on the 
Kodak Image Station 440 CF platform. Kodak 1D imaging software was utilized to quantify the 
signals via densitometric analysis. Background was subtracted from the densitometric net 
intensity values of the target protein and the loading control (-βactin), which was used to 
normalize the signal of the target protein. 
Measuring total antioxidant capacity in lungs of NSG-BLT mice 
A chromogenic Antioxidant Assay (Cayman Chemical Co) was used to determine the 
antioxidant content in total lung homogenates from uninfected, mock-infected and HIV-1 (NL4-
3 strain) infected NSG-BLT mice (10 weeks). The assay is based on the ability of antioxidants in 
the experimental sample to inhibit the oxidation of 2,2′-Azino-di- [3-ethylbenzthiazoline 
sulphonate] by metmyoglobin. Antioxidant content in the lung homogenates was quantified 
using a standard curve created with the water-soluble tocopherol analogue Trolox and 
normalized to mg of lung protein. 
Immunohistochemical detection of SOD2 in NSG-BLT mouse lungs 
Immunohistochemistry (IHC) was performed to assess SOD2 content in the lungs of 
humanized NSG-BLT mice that were either uninfected, mock-infected or infected with HIV-1 
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(NL4-3 strain) for 10 weeks. Mice we anesthetized with isoflurane followed by a sublethal IP 
injection (50 mg/kg) of ketamine and cervically dislocated after the mice were no longer 
responsive to tactile stimulus but still had spontaneous respirations. The pulmonary vascular bed 
was perfused with sterile saline and the left lung lobes were inflated with low-melting agarose to 
preserve morphology as previously described [128]. Samples were then fixed in formalin, 
paraffinized, and sectioned. Deparaffinization of lung sections was performed using an 
automated system (Gemini AS, Thermo Scientific) and epitope retrieval was accomplished by 
boiling deparaffinized lung tissue in a citrate based antigen unmasking solution (Vector 
Laboratories, pH 6.0) for 30 minutes with a 20 minutes cool down. Endogenous peroxidase 
activity was quenched by incubating in 3% hydrogen peroxide for 10 minutes. SOD2 was 
detected using a monoclonal antibody (sc-133134 mouse monoclonal IgG2b) with the 
VECTASTAIN Elite ABC Universal Kit and ImmPACT DAB Peroxidase (HRP) Substrate 
according to manufacturer's instructions (Vector Laboratories). Slides were incubated for 10 
seconds in light green counterstain (American Master Tech), cleared using an automated 
protocol (Gemini AS, Thermo Scientific) and mounted. Images were acquired under bright-field 
illumination with a Nikon Eclipse E600 microscope. 
Results 
In silico analysis of potential Sp-mediated regulatory regions upstream of sod2 ORF 
Using open sourceware programs MatInspector and PhysBinder, we performed in silico 
analysis of DNA sequences up to −3400 bp upstream of the sod2 TSS and identified clusters of 
predicted Sp binding sites. Sp1 and Sp3 are known to most strongly regulate transcription from 
regions containing clusters of binding sites. Importantly, there was a large Sp-binding cluster 
predicted between −210 and −584 that likely represented a bona fide Sp-element as it contained 
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38 predicted Sp-binding sites (Fig. 2.1A). Other clusters of potential Sp-binding sites were 
detected further upstream, though these sites were predicted to have weaker binding affinity and 
the clusters were smaller. 
Tat modulation of sod2 regulatory regions rich in Sp-binding sites 
To determine the level of transcription from the potential distal regulatory sites that we 
identified further upstream of the sod2 proximal promoter, we transiently transfected a series of 
sod2promoter-luciferase reporter constructs, shown in Fig. 2.1B, into HeLa cells. We found that 
expression from the −584sod2-prom construct was stronger (2.3- fold, p = 0.0255) than from the 
proximal −210 region. All other constructs extending further upstream were expressed to the 
same extent as the −210 construct but none were as strong as −584 (Fig. 2A). This indicated that 
maximal expression is driven by sequences between −210 and −584 and suggested that 
sequences upstream of nucleotide −584 may actually repress the maximal expression seen with 
the −584 construct. Furthermore, the Tat protein repressed transcription of all constructs, in line 
with the previous reports that Tat represses sod2 transcription. As HeLa cells are known to have 
numerous pleomorphic defects and chromosomal instabilities related to the transformed 
phenotype, we investigated the expression of the sod2-prom constructs in human primary cells 
(HPAEC) in the presence and absence of Tat. As in HeLa cells, in HPAEC maximal expression 
occurred with the −584sod2-prom construct, which again demonstrated stronger expression than 
the basal −210 construct (5.1-fold, p < 0.0001) (Fig. 2B). Interestingly, in these cells expression 
of the −1240sod2-prom construct was repressed compared to all other constructs, although 
expression was restored further upstream with constructs −1605, −2987 and −3400sod2-prom. 
These observations suggest that in HPAEC, sequences between −584 and −1240 contain 
repressive sites, but that repression is relieved by sequences upstream of −1240. Expression from 
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all constructs upstream of −1240 is equivalent to −584 and Tat repressed expression from all 
constructs with the exception of −1240 (not statistically significant). Taken together, these data 
suggest that the proximal −210 region functions as a minimal promoter but for maximal 
expression of sod2 promoter sequences that extend out to nucleotide −584 are required, and that 
a further repressive motif might be contained between nucleotides −584 and −1240. 
Tat modulates the occupancy of Sp1 and Sp3 on sod2 regulatory regions 
Our promoter-reporter data point to the −584 construct as containing the maximal sod2 
promoter, the activity of which is, all but eliminated, by Tat in HPAEC. As Sp1 and Sp3 are the 
transcription factors principally responsible for basal sod2 transcription, we hypothesized that 
Sp-binding on the large cluster of Sp-binding sites located on the −584sod2-prom construct is 
required for maximal sod2 transcription and that the HIV-Tat protein modulates Sp-
transactivation at the −584 region of this promoter. To test this hypothesis, we used chromatin 
immunoprecipitation (ChIP) to determine the occupancy levels of Sp1 and Sp3 on the Sp clusters 
at the −584 region of the endogenous sod2 promoter in Tat-transfected HPAEC. Fig. 2.3 
demonstrates that Tat expression in HPAEC resulted in a dramatic increase in the ratio of Sp1 to 
Sp3 bound to the −584 region of the endogenous sod2 promoter (775-fold increase in ratio). This 
effect appears to be due to both an increase in the amount of bound Sp1 as well as a concurrent 
decrease in bound Sp3, suggesting a predilection for Sp1 complexes to outcompete Sp3 for 
occupancy of the endogenous sod2 promoter in the presence of Tat. 
Tat stimulates expression of endogenous SOD2 in HPAEC 
As the ChIP results indicated that Tat alters the binding of Sp1 and Sp3 on a cis-element 
of the endogenous sod2 promoter that is rich in Sp binding sites, we next sought to determine if 
Tat alters the transcription of endogenous sod2 in HPAEC. RT-qPCR showed that Tat strongly 
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stimulates (~20-fold) transcription of sod2 in HPAEC (Fig. 2.4A). Furthermore, immunoblot 
analysis showed that Tat also resulted in increased SOD2 protein levels (Fig. 2.4B and C). These 
findings are in agreement with previous observations that higher Sp1 to Sp3 ratios results in 
increased SOD2 expression.  
Tat alters total cellular Sp3 activity but not Sp1 activity 
It has been demonstrated that the Sp1 to Sp3 ratio is an important regulator of SOD2 
expression, and that Sp1 acts to stimulate expression through interaction with the sod2 promoter. 
Given that Tat stimulated endogenous expression of SOD2, possibly by altering the relative 
binding of Sp1 and Sp3 to the sod2 promoter, we next sought to address if the changes in Sp1 
and Sp3 binding to −584sod2-prom might result from changes in total cellular Sp1 and Sp3 DNA 
binding activity. Utilizing nuclear protein extracts from un-transfected and Tat-transfected 
HPAEC, we performed a DNA-binding ELISA. While Tat had no effect on the total cellular 
levels of active Sp1, the amount of active Sp3 was reduced some 20% in the presence of Tat 
(Fig. 2.5). These results demonstrate that Tat likely acts to modulate the Sp1 to Sp3 binding ratio 
through inhibition of Sp3 and not via enhancement of Sp1. 
Tat Co-immunoprecipitates with Sp3 but not Sp1 and does not affect the acetylation state 
of Sp3 
HPAEC were transfected with a Tat-expressing vector and co-immunoprecipitation 
assays performed on total cellular lysates. While Tat never appeared as a co-immunoprecipitate 
with Sp1, it did immunoprecipitate with Sp3 (Fig. 2.6). Numerous studies have reported that 
acetylation of Sp3 influences binding and transcriptional activity. Additionally, other studies 
demonstrate that Tat alters cellular acetylates and deacetylases and the cellular pathways that 
they control. In order to observe the effects of Tat on acetylation of Sp3, endogenous Sp3 was 
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immunoprecipitated from un-transfected or Tat transfected HPAEC, and the acetylation state 
probed via immunoblot with a pan-acetyl lysine antibody. Fig. 2.6B demonstrates that the 
acetylation state of Sp3 remains unchanged in the presence of Tat, which suggests that Tat may 
be impeding the ability of Sp3 to compete with Sp1 for the sod2 promoter by physical or steric 
inhibition but not by altering its acetylation state.  
Tat alters expression of Sp1 and Sp3 
Lastly, we surmised that Tat could also be altering the binding and activity of Sp1 and 
Sp3 on the endogenous sod2 promoter by affecting cellular levels of either protein. To 
investigate this, we quantified Sp1 and Sp3 transcript and protein levels in the presence and 
absence of Tat. Interestingly, Tat stimulated transcription of Sp3 by more than 4.5 fold but 
transcription of Sp1 was only changed 2-fold (Fig. 2.7), such that the relative amounts of Sp3 
and Sp1 transcription in the cells were significantly changed. Furthermore, immunoblot analysis 
confirmed that Tat changed Sp1 and Sp3 protein levels in a manner similar to the transcript 
levels. (Fig. 2.8).  
HIV-1 infection alters Sp3 and SOD2 expression in the lungs of infected humanized NSG-
BLT mice 
Given the effects of Tat on Sp1/Sp3 and SOD2 in HPAEC, we surmised that a similar 
effect might be observed in the context of HIV-1 infection. Many oxidative stress related 
inflammatory comorbidities manifest in the lungs of HIV patients, and we had previously 
demonstrated increased SOD2 expression as well as biomarkers of oxidative stress in the lungs 
of an HIV Tat-transgenic mouse model. In this study, we harvested whole lung tissue from HIV-
1 infected humanized NSGBLT mice for analysis. We thoroughly validated HIV infection of 
these mice by detecting HIV DNA in the liver and lungs and we confirmed the presence of viral 
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replication in the lungs by detecting cell-free viral RNA in bronchoalveolar lavage fluid (BALf). 
Immunoblotting assays demonstrated no detectable difference in Sp1 levels between mock 
infected and HIV infected mice (Fig. 2.10). However, in agreement with our observations in 
HPAEC, Sp3 levels were increased ~2-fold in lung tissue from HIV infected mice compared to 
vehicle control (Fig. 2.9). 
Discussion 
Repression of SOD2 by Tat provided an early clue as to one mechanism by which HIV 
may induce a pro-oxidant environment, and it was subsequently demonstrated that the viral 
manipulation of SOD2 was achieved through modulation of Sp1/Sp3 activity by Tat [133]. Sp1 
and Sp3 are highly homologous transcription factors with conserved DNA binding domains 
which often compete to occupy the same nucleotide sequences. Interestingly, Sp1 activity has 
been demonstrated to enhance viral replication via synergism with NF-κB as well as by 
facilitating viral particle assembly [150], [151]. Conversely, Sp3 has been demonstrated to have 
a repressive effect on the HIV LTR [152], demonstrating the dichotomous activity of these two 
highly similar transcription factors. While these studies provided insight into the mechanisms by 
which SOD2 may be effected by Tat, the Tat mediated interactions of Sp1 and Sp3 were only 
studied in the proximal sod2 promoter (−210 nt) and relied on transformed cell lines as well as 
Sp factor deficient Drosophila S2 cells. We have hypothesized that additional Sp binding sites in 
more distal regions of the sod2 promoter may also be affected by Tat and that expression of 
SOD2 would be consequently altered. Here, we have identified a particularly Tat sensitive region 
in a more distal location (−584 nt, DTSS) of the sod2 promoter and demonstrated that this 
sensitivity is a result of Tat mediated alteration of Sp1 and Sp3 binding, resulting in increased 
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expression of SOD2 in HPAEC. Additionally, we observed a similar increase in levels of Sp3 in 
whole lung tissue from HIV-1 infected humanized mice. 
In silico analysis revealed a large number of putative Sp binding sites in the distal sod2 
promoter out to −3406 nts from the proximal Tat sensitive site. As such, we utilized a series of 
increasingly long sod2 promoter driven luciferase constructs to observe levels of sod2 promoter 
activity in constitutively Tat expressing HeLa cells (HeLa-TatIII) as well as in mock transfected 
(Tat(−)) or Tat transfected (Tat(+)) HPAEC. In the absence of Tat, reporter expression was 
highest from the −584sod2-pGL3B construct. In each case, the expression from −584sod2-
pGL3B was significantly higher than from the proximal −210sod2-pGL3B vector (2.3-fold 
greater in HeLa, and 5.1-fold greater in HPAEC). In TatIII cells, expression was repressed in 
every instance with the exception of −1605sod2-pGL3B (not statistically significant). When 
HPAEC were co-transfected with the sod2 promoter vectors and a Tat-expressing vector, 
expression was repressed in every instance with the exception of −1240sod2-pGL3B, suggesting 
that there were indeed Tat sensitive Sp (TSS) binding elements in the distal regions of the sod2 
promoter. ChIP analysis of the −584 sod2 promoter region in HPAEC subsequently revealed a 
dramatic shift in Sp1/Sp3 occupancy from an approximately equivalent level in Tat(−) cells to an 
~775:1 Sp1 to Sp3 ratio in Tat(+) cells. This observation is surprising as high Sp1 to Sp3 ratios 
generally result in transcriptional activation of promoters containing Sp sites, although we 
observed repression of sod2 promoter activity in the presence of Tat from our reporter 
constructs. In agreement with our ChIP analysis, SOD2 transcription as well as expression was 
enhanced by Tat in HPAEC, suggesting that the presence of Tat indeed alters Sp binding activity 
in a manner that facilitates SOD2 transcription. The dichotomy between the reporter construct 
results and cellular SOD2 levels in Tat(+) HPAEC may be explained by the fact that a powerful 
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intronic sod2 enhancer is absent in the reporters as the sod2 ORF is replaced by the luciferase 
gene. Sp1 acts to facilitate sod2 transcription by acting to bridge the promoter to the sod2 
intronic enhancer through an 11G loop in the proximal promoter [153]. In the absence of this 
enhancer, no such interaction can occur, and Tat mediated Sp1 accumulation to sod2 promoters 
on plasmids may in fact result in reduced reporter expression. 
In an effort to elucidate potential mechanisms by which Tat may alter Sp1/Sp3 binding 
affinity, we performed competitive DNA-binding ELISA with nuclear protein extracts from 
Tat(+) and Tat(−) HPAEC. Tat had no effect on Sp1 activity, while Sp3 activity was 
significantly reduced, suggesting that Tat does not enhance Sp1 activity, but rather decreases Sp3 
activity, allowing Sp1 to outcompete Sp3 for occupancy of the sod2 promoter. Tat is itself a 
transcription factor and is known to form complexes with a number of cellular transcriptional 
regulators including Lysine Acetyl Transferase 5 (Kat5) and P300/CBP-associated factor 
(PCAF). Tat represses the activity of Kat5 [154] but enhances that of PCAF [155], demonstrating 
that Tat has pleiotropic effects on different transcriptional elements. As such, we found it 
reasonable to hypothesize that Tat may complex or otherwise interact directly with either Sp1 
and/or Sp3 in order to elicit the effects observed in HPAEC. Endogenous Sp3 co-
immunoprecipitated with Tat in HPAEC, while Sp1 did not, indicating that Tat may alter Sp3 
binding activity through direct interaction and physical or steric inhibition. While Tat led to 
increased levels of Sp1 transcript (~2-fold increase), Sp3 transcription was even more highly 
upregulated by Tat (~4.5 fold), further strengthening the hypothesis that Tat interferes with Sp3 
activity through inhibition of binding to the promoter rather than by repressing expression. 
Immunoblot confirmed the RT-qPCR results, as the ratios of Sp3 to Sp1 protein reflected the 
ratios of Sp1 to Sp3 transcript in Tat (+) HPAEC. The increase in Sp3 expression may in fact be 
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a compensatory response by the cells, as Tat results in global repression of Sp3 activity, cells 
may attempt to restore this through upregulation of the gene. Sp1 and Sp3 are also known to be 
induced by oxidative stress [156], and the pro-oxidant environment elicited by Tat may also be 
driving their enhanced expression. Finally, we speculated that Sp1 and Sp3 levels as well as 
SOD2 levels would be altered in lungs in the context of HIV infection. To this end, we collected 
and probed whole lung tissue from uninfected, mock infected, or HIV-1 infected humanized 
mice for analysis. Immunoblot analysis demonstrated a significant increase in Sp3 levels, while 
no significant increase in Sp1 or SOD2 was observed. The fact that SOD2 appeared unaffected in 
HIV infected mice was surprising, and we surmised that tissues most proximal to circulating Tat 
and HIV infected cells (such as the pulmonary endothelium and lung vascular tunica media) 
would be most likely to be effected and that this was perhaps undetectable from whole tissue 
extract by Western blot. As such, we performed immunohistochemistry on lung sections from 
HIV infected and uninfected mice. Indeed, we observed an increase in SOD2 expression in 
periadventitial structures. Previous studies have demonstrated that, while SOD2 levels are 
increased in Tat transgenic animals, oxidative burden is still higher. To this end, we measured 
the total antioxidant capacity of whole lung tissue from HIV infected and uninfected mice. In 
agreement with previous observations, the total antioxidant capacity was lower, suggesting that 
























Fig. 2.1. Schematics of predicted Sp binding clusters and Sod2 promoter constructs. A) Sp-
binding clusters in sequences upstream of the sod2 transcriptional start site as predicted by 
MatInspector and PhysBinder algorithms: MatInspector predictions = pink/red, PhysBinder = 
green. Darker shades signify stronger predicted Sp binding affinity. Black arrows indicate 
locations of ChIP qPCR primers. B) Sod2-promoter-reporter constructs (sod2-prom) utilized in 
this study: Constructs of −210, −1240, −1605, −2987 and −3406 sod2-prom plasmids were a 





Fig. 2.2. Tat represses expression from sod2 promoter reporters. A) Expression from sod2-
promoter-reporter constructs in HeLa-WT and stable HeLa transfectant that constitutively 
expresses the HIV Tat protein, HeLa-TatIII. B) Expression from the sod2-promoter reporter 
constructs in HPAEC with (Tat( + )) and without (Tat(−)) co-transfection with pCP2-Tat. Firefly 
luciferase values were normalized to Renilla luciferase from co-transfected pRL-CMV plasmid. 
Shown is the Mean ± SEM of biological replicates, n ≥ 6, (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 

















Fig. 2.3. Chromatin immunoprecipitation (ChIP) analysis of Sp1 and Sp3 bound to the -584 
region of the sod2 promoter in un-transfected (Tat(−)) or pCP2-Tat101 transfected (Tat( + )) 
HPAEC. Following IP with either Sp1 or Sp3 antibodies, the number of copies of the −584-
nucleotide region of the endogenous sod2 promoter was determined by absolute qPCR via a 
standard curve generated utilizing a plasmid containing −3406sod2-promoter sequences. n = 3. 
(*p ≤ 0.05 by un-paired student's T-test). DNA that was immunoprecipitated using mouse IgG1 













Fig. 2.4. SOD2 expression in HPAEC in the presence and absence of Tat. A) sod2 transcription 
is strongly stimulated by HIV-Tat. Relative fold change calculated by the ΔΔCT method and 
normalized to GAPDH. Mean ± SEM of biological replicates, n = 6, p < 0.0001 by unpaired 
student's t-test. B and C) SOD2 protein levels are increased in the presence of Tat. Mean ± SEM 
of biological replicates, n = 4, (p ≤ 0.0001 by unpaired student's t-test). SOD2 Densitometry 












Fig. 2.5. Sp1 and Sp3 Binding activity in HPAEC in the absence and presence of Tat. Using an 
Sp-specific oligonucleotide-binding ELISA (TransAm, Active Motif), we measured the levels of 
active Sp1 (Panel A) and Sp3 (Panel B) in the nucleus of mock transfected (Tat(−)) or pCP2-
Tat101 transfected (Tat(+)) HPAEC. The signal was normalized to μg of nuclear protein. Mean ± 




















Fig. 2.6. Tat Co-Immunoprecipitates with Sp3 but does not alter Sp3 acetylation State: A) Sp3 
and Tat Co-immunoprecipitate: Sp3 was immunoprecipitated from Tat (−) or Tat (+) HPAEC 
whole cell lysate. Total input lysate and immunoprecipitate were analyzed via immunoblot for 
successful Sp3 IP and potential Tat CoIP. B) Sp3 acetylation state is not altered by interaction 
with Tat: The total input lysate and Sp3 immunoprecipitate from Panel A was also analyzed via 
immunoblot with antiacetyl-lysine antibodies. C) Acetyl lysine detection in the total protein 














Fig. 2.7. Transcription of Sp1 and Sp3 in the presence and absence of Tat in HPAEC. A) 
Transcript levels of Sp1 and Sp3 in Tat (−) (mock transfected) and Tat ( + ) (pCP2-Tat101-
tranfected) HPAEC: Relative levels of transcript calculated by the ΔΔCT method and normalized 
















Fig. 2.8. Sp1 and Sp3 protein levels in the absence and presence of Tat in HPAEC. A-B) Sp3 and 
Sp1 expression is increased in Tat ( + ) HPAEC. Whole cell extract of mock transfected (Tat (−)) 
and pCP2-Tat101-transfected (Tat (+)) HPAEC were analyzed via immunoblot for total levels of 
Sp3/Sp1. C) Fold increase of Sp3 (top band) and Sp1 in Tat ( + ) and Tat (−) HPAEC. Fold 
change in Sp expression was calculated as actin normalized Tat (+) densitometry values over 













Fig. 2.9. Sp3 expression increased in the Lungs of HIV infected mice while SOD2 did not 
change. A) Immunoblot analysis of Sp3 and Sod2 levels in total lung tissue: Protein was 
extracted from whole lung tissue of un-infected, mock-infected, or HIV-1 infected humanized 
mice for immunoblot analysis. B) Sp3 densitometry: Values shown as normalized to β-actin. (un-
infected n = 3, mock infected n = 4, HIV-1 infected n = 3). C) Sod2 densitometry: Values shown 
as normalized to β-actin. (un-infected n = 3, mock infected n = 4, HIV-1 infected n = 3). Mean ± 










Fig. 10. Sp1 expression in the Lungs of HIV infected mice. A) Immunoblot analysis of Sp1 
levels in total lung tissue of NSG-BLT Mice: Protein was extracted from whole lung tissue of 
un-infected, mock-infected, or HIV-1 infected humanized mice for immunoblot analysis. B) Sp1 
densitometry: Values shown as normalized to β-actin. (un-infected n = 3, mock infected n = 4, 












Fig. 11. SOD2 levels are increased in the lungs of HIV infected humanized NSG-BLT mice 
while total antioxidant capacity is lower A) IHC of lung tissue from HIV infected (10 weeks) and 
uninfected humanized NSG-BLT mice reveals periadventitial increase in SOD2. B) Total 
antioxidant capacity (TAC) is reduced in the lungs of HIV infected humanized NSG-BLT mice 
(n = 8) compared to uninfected mice (n = 8). Mean ± SEM of biological replicates (*p ≤ 0.05 by 
















HIV TAT DYSREGULATION OF THE NRF2 TRANSCRIPTIONAL NETWORK 
Introduction 
Our previous work has demonstrated that, although SOD2 is repressed by Tat in 
transformed cell lines, it is upregulated in PAH relevant primary human cells as well as in the 
lungs of an HIV infected humanized mouse model. However, the lungs of these animals remain 
oxidatively stressed as evidenced by reduced total antioxidant capacity, suggesting alternate 
pathways by which HIV elicits a pro-oxidant environment. The transcription factor Nuclear 
factor (erythroid-derived 2)-like 2 (Nrf2) is integral in maintaining cellular redox homeostasis, 
controlling many redox-sensitive cellular functions, and resolving inflammation [157]. Under 
physiological conditions, Nrf2 resides in the cytoplasm bound to its repressor, Keap1 [158]. The 
Nrf2 regulatory network is largely dictated by the presence of the cis-acting antioxidant response 
element (ARE) in the promoter regions of various anti-oxidant and anti-inflammatory genes. In 
response to oxidative stress, Nrf2 dissociates from Keap1 and translocates to the nucleus where it 
binds to the ARE, resulting in the activation of cytoprotective enzymes including heme 
oxygenase 1 (HO-1), sulfiredoxin-1 (SRXN-1), NADPH quinone dehydrogenase 1 (NQO1) and 
glutamate-cysteine ligase catalytic subunit (GCLC) [137], [159]. As such, Nrf2 activation elicits 
cytoprotective effects to acute and chronic oxidative insult including hypoxia, ischemic 
reperfusion, and xenobiotic exposure. HO-1 is of particular importance to the maintenance of 
pulmonary redox homeostasis and resolution of vascular inflammation. Indeed, HO-1 deficiency 
is associated with increased severity of hypoxic injury and pulmonary vascular inflammation 
[160]. Additionally, selective overexpression of HO-1 in the lungs of rodent models of 
pulmonary arterial hypertension attenuates pulmonary inflammation, mitigates hyper-
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proliferation of vascular smooth muscle cells, and prevents the formation of complex obstructive 
vascular lesions [161], [162]. While the pro-oxidant and pro-inflammatory properties of Tat are 
well established, the driving mechanisms remain elusive. Here, we demonstrate repression of 
Nrf2/ARE activity by Tat and repression of Nrf2 activated genes. In particular, we observe the 
potent repression of HO-1 by Tat both basally as well as in the presence of the potent Nrf2 
activating compound PB125. 
Materials and Methods 
Cells and generation of stable tat transfectants 
HeLa cells were transfected (Superfect reagent, Qiagen LLC) with the FLAG tagged Tat 
expressing vector pCMV-Tat-86-FLAG (Sino Biologicals). This plasmid, hereafter referred to as 
pTat-FLAG, expresses the 86 amino acid isoform of Tat from the HXB2 HIV strain. After 
overnight incubation, standard media was supplanted with media containing 200 mg/L 
Hygromycin-B (Thermo Fisher Scientific). Cells were passaged in Hygromycin-B containing 
media and serially diluted to obtain isolated molecular clones. To confirm the presence and 
expression of the Tat gene, total genomic DNA, RNA, and protein were extracted and analyzed 
via PCR, RT-qPCR and immunoblotting. To determine if Tat was biologically active in the 
stable Tat transfectant, hereafter referred to as HeLa-Tat-FLAG, the cells were co-transfected 
with a luciferase reporter driven by the HIV LTR and a control plasmid with Renilla luciferase 
expression driven from the cytomegalovirus (CMV) promoter and a dual luciferase assay 
(Promega Corp.) was performed (S1). Human Primary Arterial Endothelial Cells (HPAEC) were 
procured from Lonza (catalog # CC-2530) and cultured in Endothelial Basal Media-2 (Lonza 
catalog #: CC-3516) supplemented with endothelial growth factors optimized for aortic and 
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pulmonary arterial endothelial cells (Lonza catalog # CC-3162). HPAEC expansion was limited 
to six passages in order to prevent senescence and de-differentiation. 
PB125 
The novel Nrf2 activating compound PB125 was acquired from collaborators at the University of 
Colorado for use in this study [163]. 
Transfections, PB125 treatment, and dual luciferase assays 
Transfections were performed using the Qiagen Superfect® system according to 
manufacturer's protocol for cell lines or primary cells. To asses Nrf2/ARE activity, cells were 
transfected with an ARE driven luciferase reporter plasmid/Renilla luciferase plasmid mix 
(Cignal Antioxidant Response Reporter kit, Qiagen catalog #: 336481) according to 
manufacturer's protocol. To assess the effect of Tat on Nrf2/ ARE activity, cells were co-
transfected with the ARE-driven luciferase reporter and pTat-FLAG. At the time of washing, 
transfection media was supplanted with media containing PB125 or vehicle (0.016% ethanol) 
and incubated overnight, after which a Dual-Luciferase® assay was carried out (Dual-
Luciferase® Reporter Assay System, Promega catalog #: E1910) following manufacturer's 
protocol. For this study, 8 mg/L was the standard PB125 dose. For the dose response curve, cells 
were treated with PB125 concentrations ranging from 1 – 10 mg/L.  
Nrf2 target gene transcriptional analyses, western blots and ELISA 
Total cellular RNA was extracted from cells using Qiagen's RNeasy Mini Kit (Qiagen, 
Catalog #: 74106) according to manufacturer spin method protocol. Reactions were carried out 
as technical duplicates from experimental replicates of each condition (mock transfected or Tat 
transfected, un-treated, vehicle treated, or PB125 treated, n = 6). RTqPCR was carried out (50 ng 
total RNA/reaction) using Biorad iSCript™ Reverse Transcription Supermix (Catalog #: 
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1708841). For relative expression analysis, the average Ct values were calculated from technical 
replicates and analyzed utilizing the delta-delta Ct method, where all samples were normalized to 
GAPDH (first delta) and then compared to un-treated controls (second delta). To calculate 
absolute copy numbers, a standard curve was generated using plasmids containing the target 
sequences and normalized to copies of GAPDH. For immunoblot and ELISA assays total protein 
was extracted from cells using Mammalian Protein Extraction Reagent (Thermo Fisher, Catalog 
#: 78501) supplemented with 1 mM DTT and 1XProtease/Phosphatase inhibitor cocktail (HALT, 
Thermo Fisher catalog #: 78440). For immunoblot analysis 0.01 mg of protein per lane were 
resolved by Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis and transferred to 
Polyvinylidene fluoride (PVDF). Proteins were detected with antibodies from commercial 
sources, Santa-Cruz Biotechnology (HO-1) and Thermo Fisher (FLAG, β-actin and secondary 
HRP-conjugated anti-mouse or antirabbit). Immunoblots were imaged by chemiluminescence 
using Supersignal West Femto Maximum Sensitivity substrate (Thermo Fisher, catalog #: 
34095). Densitometry values are expressed as net intensity of the target protein (HO-1) over net 
intensity of the loading control, (βactin) from biological replicates (n = 3). 3-nitrotyrosine-
ELISA was carried out on total protein extracts using the Cell Biolabs Nitrotyrosine ELISA kit 
(catalog #: STA-305) according to manufacturer's protocol. Tat-FLAG levels were quantified 
from pTat-FLAG transfected HPAEC (n = 6) total protein extract by competitive anti-FLAG 
ELISA using the DYKDDDDK-Tag Detection ELISA Kit (Cayman Chemicals, catalog # 
501560). 
Electron paramagnetic resonance spectroscopy 
Total ROS production was measured by EPR using the superoxide sensitive spin probe 1-
hydroxy-3-methoxycarbonyl-2, 2, 5, 5-tetramethylpyrrolidine (CMH) while mitochondrial ROS 
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production was measured using the mitochondrial spin probe 1-hydroxy-4-[2-
triphenylphosphonio)-acetamido]-2,2,6,6-tetramethyl-piperidine,1-hydroxy2,2,6,6-tetramethyl-4-
[2-(triphenylphosphonio)acetamido] piperidinium dichloride (mito-TEMPO-H. Cells were 
seeded 18 h prior to the EPR measurements. CMH and mito-TEMPO-H probes were prepared in 
deoxygenated 50 mM phosphate buffer. Cells were washed and treated with CMH and mito-
TEMPO-H 0.25 mM in Krebs-HEPES buffer (KHB) containing 100 μM of a metal chelator 
DTPA to avoid direct oxidation with metal ion or hydroxyl radical generation by Fenton 
reaction. Cells were incubated for 50 min at 37°C then gently scraped and transferred to ice. 50 
μl of cell suspension was loaded in an EPR capillary tube and EPR measurements were 
performed at room temperature using Bruker EMXnano X-band spectrometer. EPR acquisition 
parameters were: microwave frequency = 9.6 GHz; center field = 3432 G; modulation amplitude 
= 2.0 G; sweep width = 80 G; microwave power = 19.9 mW; total number of scans = 5; sweep 
time = 12.11 s; and time constant = 20.48 ms. CM. Or mito-TEMPO. nitroxide radicals 
concentration was obtained by simulating the spectra using the SpinFit module incorporated in 
the Xenon software of the bench-top EMXnano EPR spectrometer followed by the SpinCount 
module (Bruker) [27]. Total protein was extracted from analyzed samples and quantified via a 
Bradford protein assay and nitroxide concentrations were normalized to total protein. 
Results 
Nrf2/ARE activity and transcriptional regulation in tat expressing cells 
Nrf2 is a transcription factor that is vital to mitigating cellular oxidative burden through 
activation of cytoprotective enzymes, which contain the cis-acting antioxidant response element 
(ARE) sequence in their promoter regions. As such, we surmised that dysregulation of the Nrf2 
signaling pathway may be involved in the increase in oxidative burden witnessed in cells 
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exposed to Tat. To asses Nrf2/ARE activity, an ARE driven luciferase reporter was transfected 
into HeLa-Tat-FLAG and HeLa wild type (HeLa-WT) and the cells were either un-treated or 
treated with the potent Nrf2 activating compound PB125 or vehicle (0.016 ethanol) for 18-h. 
Basal ARE activity, without PB125 treatment, was significantly increased in HeLa-Tat-FLAG 
cells compared to HeLaWT (fig. 3.1A), and this effect was further increased by treatment with 
PB125 (fig. 1B). We next sought to observe the transcriptional activity of two well characterized 
Nrf2/ARE driven antioxidant genes, HO-1 and SRXN1, via RT-qPCR. As expected, basal levels 
of SRXN1 in HeLaTat-FLAG cells were significantly increased, correlating with the observed 
increased ARE activity (fig. 3.1D). Perplexingly, HO-1 levels were consistently decreased in 
HeLa-Tat-FLAG cells, suggesting negative transcriptional regulation in the presence of Tat (fig. 
3.1C). We next sought to determine if exogenous activation of Nrf2, by PB125 treatment, could 
restore HO-1 transcriptional levels in HeLa-Tat-FLAG. While SRXN1 and HO-1 transcription 
were dramatically increased by PB125 treatment in HeLa-WT cells (fig. 2A and B), and while 
SRXN1 transcript levels were increased by PB125 treatment in HeLa-Tat-FLAG cells, HO-1 
transcript levels remained unchanged (Fig. 3.2-A and B). Western blot analysis confirmed that 
induction of HO-1 by PB125 was attenuated in Tat expressing cells (fig. 3.2C and D). The 
surprising observations that HO-1 levels in Tat expressing cells are basally repressed and remain 
repressed even in the presence of a potent Nrf2 activator suggest a mechanism by which Tat may 
elicit pro-oxidant properties through transcriptional repression of select antioxidant genes. 
Tat Expressing Cells Exhibit Increased Oxidative Burden and Protein Modification 
Tat is known to induce oxidative and pro-inflammatory pathways in-vitro, and the pro 
oxidant properties of Tat have been implicated in the pathological processes of chronic HIV 
associated co-morbidities including HIV associated pulmonary arterial hypertension (HIV-PAH). 
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To assess whether the cellular oxidative burden was increased by Tat, levels of cellular 
superoxide were quantified via spin trapping and Electron Paramagnetic Resonance (EPR) 
spectroscopy. HeLa-Tat-FLAG and HeLa-WT cells were incubated for 50 min with spin 
trapping probes CMH or Mito-TEMPO to detect levels of total cellular superoxide or 
mitochondrial superoxide respectively. Nitroxide levels were then quantified via electron 
paramagnetic resonance (EPR) spectroscopy and normalized to mg of protein. HeLa-Tat-FLAG 
cells demonstrated increased total cellular oxidative burden compared to their wild type 
counterparts (fig. 3.3A). Interestingly, while mitochondrial superoxide levels were significantly 
increased (fig. 3.3B), it accounts for only a fraction of the total cellular increase in superoxide, 
suggesting important contributions of cellular sources of oxygen radicals other than 
mitochondrial respiration. In addition to increased levels of reactive oxygen species, HeLa-Tat-
FLAG cells exhibited increased oxidative protein modification as measured by 3-nitrotyrosine 
ELISA of total protein extract (fig. 3.3C). Treatment with PB125 slightly reduced 3-nitrotyrosine 
levels in Tat-FLAG cells, although levels were still markedly increased compared to un-treated 
WT cells (fig. 3.4). 
Nrf2/ARE activity is repressed in HPAEC expressing tat 
The pulmonary vascular endothelium is a large endocrine organ that is profoundly 
involved in the pathogenesis of pulmonary arterial hypertension (PAH) through various 
mechanisms. Endothelial dysfunction, pro-inflammatory signaling, abnormal proliferation, and 
the aberrant production of ROS are all heavily implicated in the PAH disease process. The 
observation that HO-1 was repressed in HeLa-Tat-FLAG cells led us to surmise that Nrf2 
signaling may also be dysregulated by Tat in primary Human Pulmonary Arterial Endothelial 
Cells (HPAEC). To test whether ARE activity is sensitive to Tat in primary endothelial cells, 
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HPAEC were co-transfected with an ARE driven luciferase vector (ARE-luc) pTat-FLAG, and a 
dual luciferase assay was carried out after overnight incubation. In contrast to HeLa-Tat-FLAG 
cells, basal ARE activity was decreased ∼6 fold in Tat expressing HPAEC (fig. 3.5A). To test 
whether different concentrations of PB125 could restore ARE-luc levels in Tat (+) cells, a dose 
curve analysis was performed, with concentrations ranging from 1 to 10 mg/L. At every 
concentration, ARE-luc activity was heavily repressed in Tat (+) HPAEC (fig. 3.5B). While the 
signal in Tat (−) HPAEC plateaued at 6 and 8 mg/L, maximum ARE-luc activity was not 
achieved in Tat (+) cells even at 10 mg/L. In fact, the signal in Tat (+) cells at 10 mg/L was 
equivalent to those in Tat (−) cells at 1 mg/L, further demonstrating a potent predilection of Tat 
to inhibit the activation of Nrf2. 
Nrf2 regulated anti-oxidant and anti-inflammatory genes are repressed by tat in HPAEC 
Next, to assess activation of Nrf2/ARE driven genes, Tat-FLAG transfected (Tat (+)) and 
mock transfected HPAEC (Tat (−)) were treated with either PB125 (8 mg/L), vehicle (0.016% 
ethanol), or left untreated, and relative expression of target genes was assessed via RTqPCR 
from total cellular RNA. As seen in HeLa-Tat-FLAG cells, HO-1 transcription was significantly 
decreased in un-treated Tat (+) cells (fig. 3.6. A, C-D). Although PB125 led to an ∼14 fold 
increase in HO-1 transcription in Tat (+) HPAEC, compared to un-treated Tat (+) HPAEC, these 
levels were still well below basal HO-1 levels in untreated Tat (−) HPAEC. While SRXN1 levels 
were increased ∼4 fold in un-treated HeLa-Tat-FLAG compared to un-treated HeLa-WT, they 
were increased < 1 fold in un-treated Tat (+) HPAEC. Furthermore, SRXN1 was not 
significantly increased by PB125 treatment in Tat (+) HPAEC compared to controls whereas it 
was increased ∼2.5 fold in PB125 treated Tat (−) HPAEC (Fig. 3.6B). We further characterized 
the effect of Tat on Nrf2/ARE target gene transcriptional activation by assessing transcript levels 
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of NAD(P)H Dehydrogenase, Quinone 1 (NQO1) and glutamate-cysteine ligase, catalytic 
subunit (GCLC), both of which contain the ARE in their promoter regions. Compared to 
untreated cells, NQO1 levels were increased ∼2.6 and ∼3.6 fold by PB125 in Tat (−) and Tat (+) 
HPAECS respectively. However, basal levels of NQO1 transcript were significantly decreased in 
un-treated Tat (+) when compared to un-treated Tat (−) cells (fig. 3.7, A). While GCLC 
transcription was not significantly increased by PB125 in Tat (+) or Tat (−) HPAEC, basal levels 
of GCLC were slightly elevated across all treatments in Tat (+) compared to Tat (−) cells (fig. 
7B). We hypothesized that, due to Tat's transcriptional modulatory abilities, Nrf2 transcription 
itself may be repressed by Tat. However, Nrf2 transcription was unaffected under all conditions 
between Tat (−) and Tat (+) HPAEC, indicating post-transcriptional mechanisms of Nrf2 
inhibition by Tat (fig. 3.7C). Importantly, Tat concentrations observed in transfected HPAEC 
ranged from 4.39 to 97.62 ng/mL, well within the physiological range observed in HIV patients. 
Discussion 
 The Nrf2/ARE pathway has been the target of a large body of research centered on 
understanding redox regulation under normal physiological conditions as well as in response to 
exogenous stressors and various disease states. These efforts have led to the discovery of several 
antioxidant and anti-inflammatory genes which are regulated by Nrf2 via a cis-acting regulatory 
element located in the promoter region known as the Antioxidant Response Element (ARE). 
Targeted activation of these genes through Nrf2 have demonstrated profound cytoprotective 
effects in animal models of lung disease, including PAH [164], [165]. As such, the induction of 
these genes has been of intense therapeutic interest, and dysregulation of the Nrf2/ARE 
regulatory system continues to be implicated in the mechanisms driving such diseases [166], 
[167]. Thus, the Nrf2 pathway provided an enticing target of research in regard to mechanisms 
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by which soluble HIV factors may contribute to the pro-oxidant and pro-inflammatory 
environment of the pulmonary system of HIV patients. The HIV Transactivator of transcription 
(Tat) is an early HIV gene required for successful infection and is a critical viral transcriptional 
regulatory element. During infection, large amounts of Tat are secreted into circulation and are 
consequently internalized from the extracellular milieu by bystander cells due to the presence of 
a transducing peptide sequence in Tat's basic domain. The pulmonary endothelium represents a 
target of particular interest due to its heavy involvement in inflammatory pulmonary diseases 
such as PAH as well as its direct proximity to potentially HIV infected cells and circulating Tat 
protein. As Tat is known to regulate host cellular transcriptional and post transcriptional 
processes, we sought to determine if Nrf2 activity is sensitive to Tat in primary Human 
Pulmonary Arterial Endothelial Cells (HPAEC). Here, we have demonstrated a profound effect 
of Tat on Nrf2/ARE regulated genes including HO-1, SRXN1, and NQO1 as well as an increase 
in cellular oxidative burden.  
 We found that in a constitutively Tat expressing cell line, Nrf2/ARE activity was actually 
enhanced compared to wild-type controls, and treatment with PB125 further augmented this 
effect. Accordingly, SRXN1 transcript levels were increased in Tat expressing cells, and this was 
further stimulated by PB125. Confoundingly, HO-1 expression was severely attenuated in Tat 
expressing cells both basally and in the presence of PB125, suggesting differential regulation of 
HO-1 and SRXN1 by Nrf2. In line with this observation, total oxidative burden was greater in 
Tat expressing cells and while treatment with PB125 slightly reduced 3-nitrotyrosine levels, it 
did not normalize them back to those of un-treated wild type controls. As the pulmonary 
endothelium is heavily involved in non-infectious HIV associated lung disease, we sought to 
characterize the effect of Tat on the Nrf2/ARE regulatory network in primary Human Arterial 
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Endothelial Cells (HPAEC). In HPAEC, Tat expression resulted in markedly lower Nrf2/ARE 
activity and exogenous activation of Nrf2 by PB125 failed to restore Nrf2 activity. 
Corresponding with repression of Nrf2/ARE activity, HO-1 transcription was strongly repressed 
by Tat in HPAEC, and while treatment with PB125 enhanced HO-1 expression, these levels were 
still significantly below those seen in Tat (−) HPAEC treated with PB125. While SRXN1 
transcription was not basally attenuated, transcriptional induction by PB125 was repressed by 
Tat. NQO1 transcription was basally repressed by Tat although treatment with PB125 induced 
transcription to similar levels in both Tat (+) and Tat (−) HPAEC. Unexpectedly, GCLC 
transcription was unaffected by PB125 in all conditions, but was slightly enhanced in Tat (+) 
expressing cells. Taken together, these results suggest a predilection of Tat to interfere with 
global Nrf2 activity, with a particular predisposition for repression of HO-1. 
 While we observed that various Nrf2/ARE driven genes were transcriptionally repressed 
or refractory to exogenous activation by PB125, the most dramatic response was seen in HO-1. 
HO-1 functions as both an antioxidant and mediator of inflammation and is induced by a 
plethora of exogenous stimuli including oxidative and xenobiotic stress. Interestingly, HO-1 
knockout mice demonstrate increased systemic inflammation, hyper-susceptibility to oxidative 
stress, and right heart failure [168], [169]. Furthermore, it was demonstrated that the vascular 
protective effects of rampamycin are mediated by HO-1 in a monocrotaline rat model of PAH by 
eliciting anti-proliferative effects and attenuation of vascular remodeling [162]. Given that, in 
HPAEC, ARE activity was potently repressed by Tat as measured by an ARE driven luciferase 
construct, it is apparent that these genes are differentially regulated in the larger context of the 
Nrf2/ARE pathway. Transcriptional activation requires a coordinated response by various 
transcription factors and repressors. Small Maf proteins (sMafs) are a family of transcriptional 
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co-factors that form heterodimers with “cap n’ collar” proteins including Nrf2, which cannot 
bind DNA as monomers [170]. sMafs also form heterodimers with the transcriptional regulator 
Bach1 [171]. Bach1 is primarily a transcriptional repressor of ARE driven genes and is a critical 
component in the maintenance of cellular redox homeostasis [172]. Nrf2 dimerization with 
different sMaf family members appears to confer specific activity. For instance, Nrf2/MafK 
dimerization confers transcriptional activation to the ARE driven gene NQO1, while other ARE 
genes such as NAPDH generating enzymes are sensitive to Nrf2/MafG dimerization [173]. It has 
also been demonstrated that Bach1/MafK heterodimers act to repress transcription of HO-1 in a 
feedback loop designed to maintain normal heme levels [174]. Tat is known to regulate a number 
of host transcription factors during HIV infection, and it is possible that Tat modulates the 
dimerization of various sMafs to different transcription factors. Tat my also occupy elements 
proximal to the ARE in the promoter such as enhancer elements and proximal AP-1 sequences 
that are unique to different ARE driven genes. sMAFs may also contribute to the discrepancy in 
responses seen between HeLa cells and HPAEC, as HeLa cells are a transformed cancerous cell 















Fig. 3.1. ARE Activity and HO-1/SRXN1 Transcriptional Profile in WT and Tat-FLAG Cells 
(A) Basal ARE activity is significantly higher in TatFLAG cells. Values shown are normalized 
to renilla luciferase. Mean ± SEM of biological replicates (WT n = 3, Tat-FLAG n = 4)(**p ≤ 
0.01 by student's T-test). (B) ARE activity is enhanced in PB125 treated WT and Tat-FLAG 
cells. Cells were left untreated in culture media or treated with culture media containing 8 mg/L 
of PB125 for 18 h. Mean ± SEM of biological replicates (WT n = 3, TatFLAG n = 4) (**p ≤ 
0.01, ***p ≤ 0.001 by student's T-test) (C) HO-1 Transcription is basally repressed in Tat-FLAG 
cells compared to WT. (Values shown as absolute copy number. Mean ± SEM of biological 
replicates (n = 3) (**p ≤ 0.01 by student's T-test). (D) SRXN1 Transcription is basally enhanced 
in Tat-FLAG cells compared to WT. (Values shown as absolute copy number. Mean ± SEM of 







Fig. 3.2. Effects of Tat Expression on HO-1 and SRXN1 in Response to PB125. (A) HO-1 
transcription is induced by PB125 in HeLa-WT cells but remains repressed in HeLa-Tat-FLAG 
cells. HeLa-WT or HeLa-Tat-FLAG cells were incubated overnight with 8 mg/LPB125 or left 
un-treated, after which total RNA was extracted and RT-qPCR performed. Values shown as fold 
change relative to un-treated controls. Mean ± SEM of biological replicates (n = 3). (B) SRXN1 
transcription is induced by PB125 in both WT and Tat-FLAG cells. HeLa-WT or HeLaTat-
FLAG cells were incubated overnight with 8 mg/LPB125 or left un-treated, after which total 
RNA was extracted and RT-qPCR performed. Values shown as fold change relative to un-treated 
controls. Mean ± SEM of biological replicates (n = 3). (C-D) HO-1 protein levels in response to 
PB125 in WT and Tat-FLAG cells. HeLa-WT or HeLa-Tat-FLAG cells were incubated 
overnight with 8 mg/L PB125 or treated with vehicle (0.016% ethanol), after which total protein 
extract was harvested for SDS-PAGE and western blot analysis. Densitometry values shown as 
relative to actin loading controls. Mean ± SEM of biological replicates (n = 3) (**p ≤ 0.01 by 






Fig. 3.3. Tat Expressing Cells Exhibit Increased Oxidative Burden and Protein Modification(A) 
Total ROS is increased in HeLa-Tat-FLAG cells. Total ROS were measured by incubating cells 
with 1- Hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine-HCl (CMH) and nitroxide 
was measured via EPR spectroscopy. Values shown as nmol of nitroxide per gram of protein. 
(WT n = 6, TatFLAG n = 9) (***p ≤ 0.001 by un-paired student's T-test) (B) Mitochondrial ROS 
is increased in HeLa-Tat-FLAG Cells. Mitochondrial ROS were measured by incubating cells 
with (2-(2,2,6,6- Tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl)triphenylphosphonium 
chloride (MitoTEMPO-H) and nitroxide was measured via EPR spectroscopy. Values shown as 
nmol of nitroxide per gram protein. (n = 6) (*p ≤ 0.05 by un-paired student's T-test). (C) HeLa-
Tat-FLAG cells demonstrate increased protein nitrosylation as measured by ELISA. Total 3-
nitrotyrosine was measured by ELISA in HeLa-WT and HeLa-Tat-FLAG cells from total protein 







Fig. 3.4. HeLa-Tat-FLAG cells showed increased nitrotyrosine levels which were partially 
attenuated by PB125. Mean ± SEM of biological replicates (n = 6)) (*p ≤ 0.05, ***p ≤ 0.001 by 

















Fig. 3.5. The Effect of Tat on Nrf2/ARE Activity in Human Pulmonary Arterial Endothelial 
Cells. (A) Nrf2 activation is attenuated by Tat basally as well as in the presence of PB125. 
HPAEC were transfected with ARE-luc or co-transfected with ARE-luc and a plasmid 
expressing Tat-FLAG (pTatFLAG) and media containing 8 mg/ L PB125 was added at the time 
of washing. A dual luciferase assay was carried out after overnight incubation. Mean ± SEM of 
biological replicates (Tat (−) PB125(+) n = 3, Tat (+) PB125(+) n = 3, Tat (−) PB125(−) n = 13, 
Tat (+) PB125(−) n = 15). (***p ≤ 0.001 by unpaired student's T-test). (B) PB125 Dose 
Response in Tat+/-HPAEC. HPAEC were transfected with ARE-luc alone or co-transfected with 
ARE-luc and pTat-FLAG and media containing 1 to 10 mg/L PB125 was added at the time of 
washing. A dual luciferase assay was carried out after overnight incubation. Values graphed as 














Fig. 3.6. Effects of Tat on HO-1 and SRXN1 Expression in HPAEC. (A) Tat represses HO-1 
transcription in HPAEC. Cells were mock transfected or transfected with pTat-FLAG and 
incubated overnight with either regular growth medium or medium supplemented with vehicle 
(0.016% ethanol) or PB125 (8 mg/L). Total RNA was collected after overnight incubation and 
RT-qPCR was performed. Values shown as fold change relative to Tat (−) un-treated controls. 
Mean ± SEM of biological replicates (n = 6). (B) SRXN1 transcriptional induction is refractory 
to PB125 treatment in Tat expressing HPAEC. Experiment carried out as in A. Mean ± SEM of 
biological replicates (n = 6). (C-D) Induction of HO-1 Expression by PB125 is attenuated by Tat 
in HPAEC. Transfections and PB125 treatments were performed as in A. Total protein extracts 
were collected after overnight incubation for immunoblot analysis. Densitometry values 
expressed as relative intensity normalized to betaactin. Mean ± SEM of biological replicates (n = 








Fig. 7. NQO1, GCLC, and Nrf2 Transcript levels in HPAEC. (A) Tat represses NQO1 basally 
(B) GCLC transcription is unaffected by PB125 in HPAEC but is enhanced by Tat. (C) Nrf2 
transcription is unaffected by PB125 and Tat in HPAEC. Cells were mock transfected or 
transfected with pTat-FLAG and either left untreated or were treated with vehicle (0.016% 
ethanol) or PB125 (8 mg/L) for 18 h. RT-qPCR was performed from total RNA and normalized 
to GAPDH. Values are shown as fold change relative to Tat (−) un-treated controls. Mean ± 
SEM of biological replicates (n = 6) (*p ≤ 0.05, **p ≤ 0.01 by un-paired student's T-test). (UT = 












DISCUSSION, FUTURE DIRECTIONS, AND FINAL COMMENTS 
Discussion 
SOD2 expression is enhanced by Tat in HPAEC and HIV infected mice 
 The repression of SOD2 expression by Tat has long been accepted as a mechanism by 
which HIV infection induces a pro-oxidant state. First reported by Flores et. al in 1993, Tat 
expressing HeLa cells were seen to have reduced SOD2 activity and transcript levels as well as 
increased markers of oxidative protein damage compared to wild type counter parts [175]. It was 
later determined that this effect was mediated through alteration of Sp1/Sp3 occupancy of the 
proximal (-210 nt) sod2 promoter in drosophila S2 cells and HepG2 liver carcinoma cells  [133]. 
Our results, however, indicate that SOD2 expression is enhanced in physiologically relevant 
primary HPAEC, which was mediated through decreased occupancy of Sp3 to the sod2 
promoter; in particular, the Sp binding site rich -584 nt region. This effect was recapitulated in 
HIV infected humanized mice, in which SOD2 levels were elevated in the periadventitial spaces 
of the lungs, although total antioxidant capacity from lung tissue remained lower than wild type 
levels. These findings are in line with the observations that SOD2 expression was increased in 
the lungs of a Tat transgenic mouse line. Lung tissue from these mice, similar to lung tissue from 
HIV infected humanized mice, nonetheless remained significantly oxidatively stressed as 
evidenced by elevated protein nitrosylation and increased activity of a number of antioxidant and 
inflammatory genes including NF-κB and thioredoxin interacting protein (TxNIP) [176]. As 
such, it has been postulated that the elevated levels of SOD2 in these animals was a result of 
constitutive oxidative stress induced by Tat through alternate mechanisms.  
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While our research suggests that Tat may result in enhanced SOD2 expression by binding 
to Sp3 and inhibiting its ability to bind to the sod2 promoter, more research is needed to 
empirically demonstrate that increased levels of SOD2 are not simply a result HIV induced 
production of excess ROS in the lungs of these animals. To address this question, the oxidative 
burden and TAC in the lungs of HIV infected mice should be normalized to WT levels through 
treatments with antioxidant compounds, and the subsequent SOD2 levels examined. 
Furthermore, Sp3 knockdown/knockout experiments in HPAEC could help to support or refute 
the notion that Tat mediates the increased expression of SOD2 through interference of Sp3 
promoter binding activity.  
The lungs of HIV infected mice are oxidatively stressed despite elevated SOD2 
One of our most interesting observations was the fact that TAC was reduced in total lung 
tissue from HIV infected animals despite a clear upregulation of SOD2 expression in animal lung 
sections. Our research on the effects of Tat on the Nrf2/ARE transcriptional network in HPAEC 
suggest an alternate mechanism by which HIV may induce a chronic pro-oxidant environment 
independent of SOD2. We observed that expression of an ARE driven reporter gene was potently 
repressed by Tat in HPAEC, and that multiple Nrf2/ARE regulated genes were either repressed 
basally by Tat and/or refractory to exogenous pharmaceutical stimulation in the presence of Tat. 
While we observed these effects in a number of genes (including HO-1, SRXN1, and NQO1), 
Nrf2 is responsible for regulating and ever growing list of dozens of genes involved in 
glutathione synthesis and regeneration, ROS detoxification, NADPH regeneration, and 
heme/iron metabolism [177]. As such, any viral element that interferes with NRf2 function is 
poised to induce profound physiological effects on its host. Additionally, using EPR 
spectroscopy, we have demonstrated that a constitutively Tat expressing cell line generates 
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markedly increased levels of O-2, the majority of which is not mitochondrial in origin. This is in 
line with our observations that SOD2 levels are increased in HIV infected mice even though the 
lungs are still oxidatively stress, as SOD2 is a mitochondrial enzyme. While in this work we did 
not explore the effects of HIV infection on Nrf2 in HIV infected mice, our observations suggest 
that Tat mediated suppression of Nrf2 could reasonably be a mechanism by which HIV results in 
chronic cardiopulmonary oxidative stress, and more research into this putative mechanism and 
physiological consequences is warranted.  
Nrf2/ARE genes are differentially regulated 
 Nrf2 activation involves a number of steps including stabilization of Nrf2 by release from 
the E3-ubiquitin ligase adapter Keap1, phosphorylation of Nrf2 by PI3K, nuclear import, and 
binding to ARE sequences in the promoter regions of Nrf2 regulated genes resulting in 
transactivation [178], [179]. However, we have made a number of confounding observations 
suggesting that Nrf2 transactivated genes are differentially regulated within and across cell types. 
We first utilized a stable Tat transfected HeLa cell line to observe the effects of Tat on baseline 
Nrf2 activity as well as activation by the compound PB125. Firefly luciferase reporter constructs 
driven by tandem ARE repeats demonstrated significantly increased levels of Nrf2 activation in 
both un-treated and PB125 treated Tat expressing cells compared to wild-type counterparts, 
suggesting increased levels of oxidative stress induced by Tat but no direct effect on Nrf2 
mediated gene transactivation. However, upon analysis of a canonical Nrf2/ARE driven 
cytoprotective gene (HO-1), we observed potent transcriptional repression of HO-1 by Tat in 
both un-treated and PB125 treated cells. Further confounding the issue, we observed 
dramatically increased transcript levels of another canonical Nrf2 activated gene (SRXN1) in 
both un-treated and PB125 treated Tat expressing cells. In primary HPAEC, however, we 
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observed that expression from our reporter constructs was potently inhibited by Tat, and that 
HO-1 was repressed both basally and in the presence of PB125. However, SRXN1 transcription 
was not enhanced by Tat, and was refractory to stimulation by PB125 in the presence of Tat. 
Transactivation by Nrf2 is contingent on binding to promoter AREs by co-factors, including 
small maf proteins (sMAFs), the class of which is known to dictate which classes of ARE driven 
genes are expressed [170]. Phosphorylation at various sites of Nrf2 by a number of kinases, 
including PI3Ks and MAPKs are also known to elicit differential effects on Nrf2 gene activation 
[180]. Combined with our observations that Tat does not elicit a change in Nrf2 levels itself,  
these co-factors represent enticing targets for future research endeavors seeking to shed light on 
the mechanisms by which Tat represses specific Nrf2/ARE driven genes but not others.  
The transactivation of certain select genes have become common surrogates for the 
activation (or lack thereof) of Nrf2. Our results indicate that researchers should take caution 
when choosing their criteria for Nrf2 activation as, depending on the cell type and/or system, 
even ARE driven reporter assays may not accurately reflect the true effects on the larger Nrf2 
transcriptional network and resulting physiological consequences.  
Tat potently represses HO-1 Expression 
 One consistent observation across treatments and cell types was the predilection of Tat to 
potently repress transcriptional activation of HO-1. This effect is particularly noteworthy due to 
the important role of HO-1 in the resolution of inflammation and ROS reduction in the lungs. 
Proper regulation of HO-1 plays a critical role in maintaining tissue homeostasis in response to 
acute lung injury and hypoxia [168], [181], and reduced levels of HO-1 is associated with the 
development of interstitial fibrotic lung disease [182]. Furthermore, the anti-proliferative effects 
of HO-1 in pulmonary vascular cells is implicated in the therapeutic benefit elicited by 
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rapamycin in a monocrotaline induced rat model of PAH [183]. As such, the consistent 
repressive effects of Tat observed in our cell models warrants further exploration in animal 
models of HIV infection and associated inflammatory pulmonary co-morbidities. In fact, HIV 
mediated repression of HO-1 in monocyte derived macrophages (MDMs) has been associated 
with the development of severe HIV associated neurocognitive disease (HAND), and this 
repressive effect was not mediated by Nef, Vpr, or Vpu [184]. Interestingly, HO-1 activity has 
been implicated in the inhibition of HIV replication in human PBMCs infected with laboratory 
strains as well as various clinical isolates. Furthermore, induction of HO-1 expression in 
humanized mice by the administration of hemin resulted is a significant suppression of HIV 
infection [185]. From a purely virological standpoint, suppression of HO-1 by Tat may represent 
a mechanism by which HIV counteracts this putative host defense mechanism.  
Concluding Remarks 
 The ambiguous etiology of PAH and the ever-evolving understanding of HIV persistence 
and the molecular and physiological consequences render any endeavor aiming to elucidate the 
exact mechanisms driving HIV-PAH pathophysiology a daunting task. While we do not draw 
any conclusions as to a causal relationship between HIV factors and HIV-PAH, we provide 
compelling evidence that the HIV Tat protein induces a pro-oxidant cellular and tissue 
environment through the dysregulation of redox sensitive factors, and that Tat represses the 
expression of genes that are heavily involved in resolving inflammation, maintaining redox 
homeostasis, and ameliorating pulmonary and cardiovascular injury. While humanized mice are 
a valuable model of HIV infection, certain aspects of their physiology represent significant 
challenges to researching HIV-PAH. In particular, mice are not known to demonstrate the same 
type of pathological vascular remodeling that is seen in many human patients and primate 
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models, with the exception of specific transgenic lines (e.g. Fra-2 mice) [186]. However, 
remaining lung tissue samples from out HIV infected mice remain invaluable samples in which 
to explore Nrf2/ARE gene expression (the Keap1-Nrf2 system is highly conserved) and markers 
of pulmonary EC and SMC proliferation, senescence, and or apoptosis/necrosis. Furthermore, 
modern RNA seq methods and technologies, specifically Anchored Multiplex PCR, will allow 
for transcriptomic and long non-coding RNA analysis from fixed paraffin embedded samples.  
 The fact that Tat represses SOD2 expression in transformed cell lines combined with 
observations that total SOD activity has been seen to be reduced in the serum of HIV infected 
patients has led to the notion that Tat mediated repression of SOD2 is a mechanism by which 
HIV infection induces pro-oxidant states in human patients. However, there is a paucity of 
sufficient data to support this claim. A more careful look at the literature reveals that the reduced 
SOD capacity in human patients is most likely a result of a reduction of SOD1 and SOD3 levels 
[187], [188]. Furthermore, SOD2 levels in HIV transgenic and HIV infected murine models have 
been seen to be either unchanged or even increased [105], [128], [189]. Our observations that Tat 
increases SOD2 levels in HPAEC are in line with these observations, and lead us to believe that 
there are alternate mechanisms by which HIV, specifically Tat, contributes to redox related 
cellular pathologies. Our observations that Tat interferes with the Nrf2/ARE signaling network in 
HPAEC, resulting in decreased transcription of several key antioxidant and inflammation 
resolving genes, provides evidence as to a new potential mechanism by which HIV may 
contribute to the development of HIV-PAH through the induction of a pro-oxidant lung 
environment (outlined in figure 4.1). While the effects of HIV infection on Nrf2 activity in the 
lungs of human patients and animal models remain relatively unexplored, the Nrf2/ARE network 
has been a target of interest in exploring putative redox related mechanisms of HIV associated 
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neurocognitive disorders (HANDs), and Nrf2/ARE regulated genes (HO-1 in particular) have 
been observed to be downregulated in cortex tissue of HIV patients [184]. As such, we propose a 
model in which the pulmonary HIV reservoir serves as a source of extracellular Tat which is 
internalized by lung bystander cells, resulting in downregulation of critical Nrf2/ARE driven 
antioxidant genes in PAH associated cell types which may include the pulmonary vascular 
endothelium. Further research is warranted to explore these potential mechanisms in animal 















Figure 4.1. Summary of contributing factors to the development of HIV-PAH and putative role of 
soluble viral factors in contributions to HIV-PAH cellular pathologies. A. Several soluble viral 
factors have been implicated in contributing to the development of HIV-PAH including Gp120, 
Tat, and Nef. B. While Tat has been seen to repressed MnSOD expression in transformed cell 
lines, MnSOD expression is increased by Tat in HPAEC; a result which is recapitulated in the 
lungs of HIV infected humanized mice. C. Despite increased MnSOD levels, there is evidence 
that cells and mice remain oxidatively stressed. The observation that Tat represses Nrf2/ARE 
activity and certain Nrf2 driven antioxidant genes provides a putative mechanism by which Tat 
elicits a pro-oxidant environment. D. Genetic predisposition and external risk factors which 
contribute to chronic pro-inflammatory and pro-oxidant states additionally contribute to an 
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HIV and the DNA Damage Response: Tat, Tip60, and ATM 
 When I first joined the Cota-Gomez lab, I took a deep dive into the literature in an 
attempt to carve out an original thesis project idea that was substantially supported by the field. 
Whether I succeeded or not is up to interpretation, however, I became extremely interested in the 
mechanisms by which soluble HIV factors manipulate and modulate the host DNA Damage 
Response (DDR) and the potential pathological effects on bystander cells in the pulmonary 
vasculature. In particular, I set my sights on the Tat Interacting Protein 60 kDa (Tip60) 
acetyltransferase, which was discovered as a Tat interacting partner. The Tat/Tip60 relationship 
is unique in that, unlike other host acetyltransferases which Tat relies on for acetylation and 
activation, Tip60 activity is repressed by Tat through various mechanisms. Furthermore, it has 
been demonstrated that Tip60 activity is absolutely critical for the activation of canonical DNA 
damage response signaling of the DDR master regular Ataxia Telangiectasia Mutated (ATM). As 
such, I hypothesized that Tat mediated interference of Tip60 activity could result in aberrant 
ATM signaling and result potentially in the accumulation of DNA damage and induction of pro-
proliferative cellular phenotypes in pulmonary vascular cells exposed to Tat. For a more in depth 
and comprehensive review of the roles of HIV and the DDR in HIV-PAH, readers may reference 
my published review article titled “The DNA Damage Response and HIV-Associated Pulmonary 
Arterial Hypertension [190]. ” 
Background  
The histone acetyl transferase Tip60 (Tat interacting protein 60 kDa) was discovered as an 
interacting partner of Tat, though the cellular function of Tip60 as well as the biological 
importance of the Tat/Tip60 interaction were unknown for years after its discovery [191]. Tip60 
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has since been demonstrated to be integral to DNA damage repair by regulating chromatin 
remodeling, gene transcription activation, and activation of DDR factors [192]. It was later 
discovered that Tat inhibits the activity of Tip60 both through inhibition of the HAT domain as 
well as by facilitating its proteasomal degradation [120], [154]. This ultimately results in a pro-
survival cellular phenotype in which DNA damage fails to induce caspase mediated apoptosis. 
Moreover, it has recently been discovered that Tip60 is responsible for activation of the 
aforementioned DDR master regulator ATM through acetylation of lysine 3016. This event 
immediately precedes and is necessary for auto-phosphorylation and dissociation/activation of 
ATM dimer subunits [193], [194]. 
 ATM is a large PI3K-like kinase which serves as a master regulator of the DDR and is 
responsible for orchestrating appropriate cellular responses to genotoxic stress such as ROS 
[195]. ATM exists as a catalytically inactive dimer, and it has been well established that 
autophosphorylation is absolutely necessary for dissociation of the homodimer into a 
catalytically active monomer kinase [196]. However, recent research has brought to light the role 
of a preceding acetylation event necessary for autophosphorylation and activation [197]. It has 
been demonstrated that the acetyltransferase Tip60 is the primary activator of ATM, and 
disruption of Tip60 activity abolishes activation of ATM even in the presence of potent 
activators. We have hypothesized that Tat interacts with and disrupts Tip60 activity, resulting in 
impaired activation of ATM and thus an impaired DNA damage response which may result in 
the accumulation of somatic mutations and a pro-proliferative/anti-apoptosis cellular phenotype. 
A simplified schematic of Tip60/ATM signaling is provided in Figure A1.   
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The Tat/Tip60 interaction 
The interaction of Tat and Tip60 was first demonstrated using a two-hybrid screening 
approach in yeast, and subsequent research utilized predator prey methods such as 
chromatography with purified proteins to explore the interacting domains of Tat and Tip60 ex 
vivo [191]. As such, we sought to utilize co-immunoprecipitation and site directed mutagenesis 
to explore this interaction in-vitro. We demonstrated that Tip60 co-immunoprecipitates from 
transfected HeLa cells as well as primary HPAEC, thus demonstrated a strong in vito interaction 
(Fig a2A and B). Creaven et al. had previously demonstrated that a 12 amino acid lysine/arginine 
(K/R) rich motif in the basic domain of Tat as being critical for the binding of Tat to Tip60 and 
resulting inhibition of Tip60 activity [154]. This conclusion was reached by sequential deletions 
of the C and N terminal domains of Tat followed by affinity chromatography. However, at no 
point did the authors create a mutant in which only this domain alone was deleted. As such, we 
decided to explore this interaction as a mutant Tat lacking Tip60 binding activity would provide 
a valuable tool in exploring the Tat/Tip60/ATM signaling paradigm. To accomplish this, we 
employed site directed mutagenesis and co-immunoprecipitation. However, we observed that 
deletion of the K/R domain of Tat did not result in diminished co-immunoprecipitation of Tat 
and Tip60 (fig. a2C). As such, this proved to be an inviable tool for our research purposes.  
ATM activation in the presence of Tat 
Subsequent acetylation of ATM by Tip60, ATM auto-phosphorylates at serine residue 
1981 before dissociation and activation. Thus, phosphor-ser-1981 is a canonical marker of ATM 
activation. We postulated that ATM would be less activated in the presence of Tat, due to the 
repressive effects of Tat on Tip60. We probed for ATM activation using Phospho-specific 
antibodies for serine 1981 on ATM. While we had evidence in HeLa cells that ATM may in fact 
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be less activated when stimulated by the DNA damage/free radical producing compound 
doxorubicin hydrochloride (Dox-HCL) in Tat expressing HeLa cells, our results in HPAEC were 
inconsistent, and may in fact point to increased activation of ATM by Tat, potentially due to 




































Figure a1. Simplified diagram of the Tip60/ATM signaling axis. Tip60 acetylates ATM at lysine 
residue 3016 resulting in activation of the kinase monomer and induction of a signaling cascade 
culminating in double strand DNA (dsDNA) breakage repair, cell cycle arrest, or programmed 
cell death in the event of irreparable DNA damage and/or constitutive cell stress. HR = 























Figure a2. Tat co-immunoprecipitates with Tip60 in vitro. A-B: Tip60 HeLa cells (A) or HPAEC 
(B) were transfected with a FLAG tagged Tat vector, parent vector, or un-transfected, and Tip60 
was immunoprecipitated. Tip60 immunoprecipitate (left panels) or Tat co-immunoprecipitate 
(right panels) was detected via western blot. C: A549 cells were transfected with either parent 
vector, FLAG tagged Tat (Tat-86-FLAG), or FLAG tagged Tat with the K/R rich domain deleted 
(ΔK/R-Tat). Tip60 was immunoprecipitated and Tat co-immunoprecipitate was detected via 























Figure a3. Activation of ATM in Tat expressing Cells A) HeLa-WT and HeLa-TatIII cells were 
treated with 3 uM of the DNA damaging agent doxorubicin-HCL or un-treated for 48 hours. 
Whole cell extracts were then probed for total ATM or  pSer-1981 ATM via western Blot. 
Loading control = Beta-actin. B) HeLa-WT and HeLa-TatIII cells were treated with 3 uM 
doxorubicin-HCL or un-treated for 30 minutes, 1, 2, 5, and 24 hours, after which whole cell 











Fig a4. Activation of ATM in the presence of Tat in HPAEC: HPAEC were treated for 1, 2, 5, and 
18 hours with 1.5 uM dox-HCL, after which whole cell extracts were harvested and the ATM 












Supplemental Materials: Chapter II 
 
Ch. II Supplemental Materials Figure 1. Tat does not co-immunoprecipitate with Sp1 in 
HPAEC. Sp1 was immunoprecipitated from whole cell lysate of HPAEC 18 hours after 
transfection with pCP2-Tat101 plasmid. Total input lysate (TIL) and the immunoprecipitate (IP) 















Ch. II Supplemental Materials Figure 2: Validating HIV-Infection of NSG-BLT Mice. Ten 
weeks after infection of NSG-BLT mice with NL4-3 strain of HIV, we performed nested PCR 
for the HIV env gene with total DNA extracted from homogenized lung (lng) and liver (lvr) 
tissue infected (top panel) and un-infected (bottom panel) NGS-BLT Mice.  Plasmid pBR-NL43-
IRES-eGFP-nef+, 3.5 fg, was used as the positive control.  As negative controls we included a 
no template reaction (NTC) and the product of the outer reaction only (OR) from the + control 









Mouse ID / Infection Status Copies/ml BALf 
I1/HIV-Infected; 10 weeks 3.78x103 
I2/HIV-Infected; 10 weeks 3.78x103 
I3/HIV-Infected; 10 weeks 6.60x102 
I4/HIV-Infected; 10 weeks 5.73x103 
I5/HIV-Infected; 10 weeks 8.99x102 
I6/HIV-Infected; 10 weeks 2.50x104 
I7/HIV-Infected; 10 weeks 1.08x103 
I8/HIV-Infected; 10 weeks 5.77x103 
Avg Copies/ml 5.84x103 
 
Ch. II Supplemental Materials Figure 4: HIV viral load in lungs of NSG-BLT Mice. We performed 
RT-qPCR for the HIV env gene with total viral RNA purified from cell-free bronchoalveolar lavage 
fluid (BALf) of NSG-BLT mice infected for 10 weeks with NL4-3 strain HIV. All standards and 
experimental samples were assayed in technical triplicates. Uninfected and mock-infected mice 












Ch. II Supplemental Materials Figure 5: SOD2 immunostaining of additional NSG-BLT Mouse 
lung sections. Representative images from the lungs of HIV infected mice demonstrate increased 






Ch. II Supplementary Table 1: Antibodies used in chapter II
 
Ch. II Supplementary Table 2: Oligos used in chapter II. Sequences in red text represent the 












Host and Type Vendor Cat#
Human Sod2 IB Rabbit Polyclonal Millipore 06-984
















Human Sp1 Chromatin IP Rabbit Polyclonal Abcam ab13370









F 5' -TTACAGCCCAGACAGCTCTTC- 3'






R 5' -ACGGTGCCATGGAATTTGCC- 3'
Human Sp1 RT-qPCR Primers SP1
Human Sp3 RT-qPCR Primers SP3
Human gapdh RT-qPCR Primers GAPDH
Cloning human -584sod2 promoter fragment SOD2
Chromatin IP PCR primers flanking the -584 region of human sod2 SOD2
Human sod2 RT-qPCR Primers SOD2
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Ch. III Supplementary Table 1: Antibodies used in chapter III 
 
 

















Host and Type Vendor Cat#




FLAG Tagged Tat IB Rabbit Polyclonal Sigma-Aldrich F7425
Gene Name Gene Symbol Direction Sequence
F 5'-GACCCATGACACCAAGGACC-3'
R 5'-TCGCCACCAGAAAGCTGAG-3'
F 5'- TTCCCAGATTAGGCTGTCCTG -3'
R 5'- GTACTGAAGCGAGGGTGCTT -3'
F 5' -GACCCATGACACCAAGGACC- 3'
R 5' -TCGCCACCAGAAAGCTGAG- 3'
F 5'- CAACTACTCCCAGGTTGCCC -3'
R 5'- AATGTCTGCGCCAAAAGCTG -3'
F 5'- GCTGGTTTGAGCGAGTGTTC -3'
R 5'- CTGCCTTCTTACTCCGGAAGG -3'
F 5'- CCTCGTGGACACGATCCG - 3'
R 5' -GCTCCCAGGTACACCCTTAG- 3'
NAD(P)H Quinone Dehydrogenase 1 NQO1
Sulfiredoxin-1 SRXN1
Glyceraldehyde 3-phosphate dehydrogenase GAPDH
Glutamate-Cysteine Ligase Catalytic Subunit GCLC
Heme Oxygenase 1 HO-1
Nuclear factor (erythroid-derived 2)-like 2 Nrf2
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